Channelpedia

Kv11.1

2538 literature references associated to Kv11.1

used / unused
Pubmed id

1

364826

5

365116

Su Z et al. Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 May 17 , 113 (5748-53).

9

364694

Colatsky T et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
J Pharmacol Toxicol Methods, 2016 Jun 6 , ().

10

365194

Carbonell-Pascual B et al. Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
J. Theor. Biol., 2016 Jun 21 , 399 (92-102).

13

364743

Yamaguchi Y et al. Latent pathogenicity of the G38S polymorphism of KCNE1 K(+) channel modulator.
Heart Vessels, 2016 Jun 2 , ().

16

364733

Wu W et al. Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Card Electrophysiol Clin, 2016 Jun , 8 (275-84).

22

361354

24

361241

Gintant G et al. Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov, 2016 Feb 19 , ().

28

365584

31

365146

Liu F et al. Cotranslational association of mRNA encoding subunits of heteromeric ion channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 Apr 26 , 113 (4859-64).

35

365612

36

361408

Ichikawa M et al. Multigenerational Inheritance of Long QT Syndrome Type 2 in a Japanese Family.
Intern. Med., 2016 , 55 (259-62).

38

356722

Hassinen M et al. Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2015 Oct-Nov , 176-177 (44-51).

39

356797

Arcangeli A et al. Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat., 2015 Jul-Aug , 21-22 (11-9).

40

367837

42

362387

González Cabrera D et al. Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
J. Med. Chem., 2015 Sep 24 , 58 (7572-9).

50

366169

Lees-Miller JP et al. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
J. Mol. Cell. Cardiol., 2015 Oct , 87 (192-3).

51

366208

Melgari D et al. hERG potassium channel inhibition by ivabradine requires channel gating.
J. Mol. Cell. Cardiol., 2015 Oct , 87 (126-8).

52

357342

Frea S et al. New echocardiographic insights in short QT syndrome: More than a channelopathy?
Heart Rhythm, 2015 Oct , 12 (2096-105).

53

365901

Lee HJ et al. Mechanism of inhibition by olanzapine of cloned hERG potassium channels.
Neurosci. Lett., 2015 Nov 16 , 609 (97-102).

56

368232

Zhao H et al. Discovery of novel N-aryl piperazine CXCR4 antagonists.
Bioorg. Med. Chem. Lett., 2015 Nov 1 , 25 (4950-5).

57

368233

Delaunois A et al. Cardiac safety of lacosamide: the non-clinical perspective.
Acta Neurol. Scand., 2015 Nov , 132 (337-45).

62

357738

Leren IS et al. Cardiac Mechanical Alterations and Genotype Specific Differences in Subjects With Long QT Syndrome.
JACC Cardiovasc Imaging, 2015 May , 8 (501-10).

64

348613

65

358184

66

355366

Perry MD et al. Getting to the heart of hERG K(+) channel gating.
J. Physiol. (Lond.), 2015 Mar 27 , ().

67

355367

68

367434

Goodchild SJ et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J., 2015 Mar 24 , 108 (1435-47).

69

367435

70

367436

71

348493

Biliczki P et al. The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation.
Naunyn Schmiedebergs Arch. Pharmacol., 2015 Mar 20 , ().

72

358075

73

348537

75

359312

Yang L et al. Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.
Anesthesiology, 2015 Mar , 122 (571-84).

76

356645

Han SN et al. [Effects of midazolam on hERG K+ channel].
Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2015 Mar , 31 (143-7).

77

356913

82

357816

Wu W et al. The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Mol. Pharmacol., 2015 Jun , 87 (1042-50).

84

364041

Zhao X et al. Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Basic Clin. Pharmacol. Toxicol., 2015 Jun , 116 (516-23).

87

356691

Stattin EL et al. Genetic screening in sudden cardiac death in the young can save future lives.
Int. J. Legal Med., 2015 Jul 31 , ().

88

356707

Zhang W et al. Kcnh2 and Kcnj8 Interactively Regulate Skin Wound Healing and Regeneration.
Wound Repair Regen, 2015 Jul 28 , ().

89

362794

Yue Y et al. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
Circulation, 2015 Jul 28 , 132 (230-40).

91

356790

Lee S et al. Cellular mechanisms for trazodone-induced cardiotoxicity.
Hum Exp Toxicol, 2015 Jul 17 , ().

93

357437

95

366724

Issa NP et al. QT interval prolongation in a patient with LQT2 on levetiracetam.
Seizure, 2015 Jul , 29 (134-6).

99

348969

100

349039

Wiśniowska B et al. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
J Appl Toxicol, 2015 Jan 5 , ().

102

350133

Vedani A et al. OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data.
Toxicol. Lett., 2015 Jan 22 , 232 (519-32).

103

348893

Saber S et al. Complex genetic background in a large family with Brugada syndrome.
Physiol Rep, 2015 Jan 1 , 3 ().

104

358978

Lynch SM et al. N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (48-52).

105

360806

Riuró H et al. Genetic analysis, in silico prediction, and family segregation in long QT syndrome.
Eur. J. Hum. Genet., 2015 Jan , 23 (79-85).

108

349322

110

363870

Chae YJ et al. Effects of donepezil on hERG potassium channels.
Brain Res., 2015 Feb 9 , 1597 (77-85).

113

348729

Männikkö R et al. Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol., 2015 Feb 12 , ().

116

348817

Vijayvergiya V et al. Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices, 2015 Feb , 17 (12).

117

349491

124

361639

126

361749

127

362069

Sviripa VM et al. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.
Org. Biomol. Chem., 2015 Dec 15 , 14 (74-84).

128

356537

Sundby E et al. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Eur J Pharm Sci, 2015 Dec 1 , 80 (56-65).

131

368091

Liang D et al. [Expression of human ether-a-go-go-related gene in laryngeal carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015 Dec , 29 (2160-3).

132

367031

134

362625

Chen J et al. Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel.
J. Biol. Chem., 2015 Aug 21 , 290 (21101-13).

139

356610

140

356609

141

366810

142

367187

Osterbur ML et al. An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
Hum. Mutat., 2015 Aug , 36 (764-73).

145

367292

Zhang C et al. Identification of Low-Risk Adult Congenital LQTS Patients.
J. Cardiovasc. Electrophysiol., 2015 Aug , 26 (853-8).

146

362724

148

356577

Zhang J et al. [Effects of allitridum on rapidly delayed rectifier potassium current in HEK293 cell line].
Nan Fang Yi Ke Da Xue Xue Bao, 2015 Aug , 35 (1128-32, 1142).

150

363469

Chae YJ et al. Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
Eur. J. Pharmacol., 2015 Apr 5 , 752 (1-7).

153

363096

Ferreiro SF et al. Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins (Basel), 2015 Apr , 7 (1030-47).

154

367205

155

364097

161

356933

166

357016

Pugsley MK et al. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Handb Exp Pharmacol, 2015 , 229 (149-203).

168

366937

Martelli A et al. Inhibitors of the renal outer medullary potassium channel: a patent review.
Expert Opin Ther Pat, 2015 , 25 (1035-51).

169

366294

Shi YQ et al. Mechanisms underlying probucol-induced hERG-channel deficiency.
Drug Des Devel Ther, 2015 , 9 (3695-704).

173

366166

Shi YQ et al. High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Cell. Physiol. Biochem., 2015 , 37 (284-96).

174

366101

Lastraioli E et al. hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
Biomed Res Int, 2015 , 2015 (896432).

175

363305

Giacomini E et al. A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Comb. Chem. High Throughput Screen., 2015 , 18 (269-80).

179

362900

Jing Y et al. In silico prediction of hERG inhibition.
Future Med Chem, 2015 , 7 (571-86).

181

348696

182

348622

183

349137

186

350232

Gibson JK et al. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (255-67).

187

350741

Mirams GR et al. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (246-54).

188

353366

189

354195

191

350414

192

359865

Brudeli B et al. Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Sep 15 , 24 (4598-602).

193

350785

197

344657

Bartok A et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon, 2014 Sep , 87 (6-16).

198

359953

Kim Y et al. Novel thienopyrimidinones as mGluR1 antagonists.
Eur J Med Chem, 2014 Oct 6 , 85 (629-37).

199

349752

Kauthale RR et al. Assessment of temperature-induced hERG channel blockade variation by drugs.
J Appl Toxicol, 2014 Oct 28 , ().

200

359870

Kratz JM et al. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
J Chem Inf Model, 2014 Oct 27 , 54 (2887-901).

202

359568

Perlmutter JI et al. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
J. Med. Chem., 2014 Oct 23 , 57 (8540-62).

203

359644

204

360248

Nogawa H et al. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Eur. J. Pharmacol., 2014 Oct 15 , 741 (336-9).

205

350391

Olde Nordkamp LR et al. Syncope in genotype-negative long QT syndrome family members.
Am. J. Cardiol., 2014 Oct 15 , 114 (1223-8).

206

367922

Wu W et al. Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
J. Physiol. (Lond.), 2014 Oct 15 , 592 (4465-80).

208

360955

209

350095

211

359387

Linder T et al. Structural insights into trapping and dissociation of small molecules in K⁺ channels.
J Chem Inf Model, 2014 Nov 24 , 54 (3218-28).

212

349500

Colenso CK et al. Voltage sensor gating charge transfer in a hERG potassium channel model.
Biophys. J., 2014 Nov 18 , 107 (L25-8).

214

349976

217

359340

221

364317

Zhao X et al. The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Naunyn Schmiedebergs Arch. Pharmacol., 2014 Nov , 387 (1079-89).

223

345349

Frolov RV et al. Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol., 2014 May 5 , 730 (61-71).

228

353412

Wang Q et al. Gain-of-function KCNH2 mutations in patients with Brugada syndrome.
J. Cardiovasc. Electrophysiol., 2014 May , 25 (522-30).

229

345489

Hill AP et al. Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol., 2014 May , 85 (769-76).

233

353179

234

355305

Koenig X et al. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Addict Biol, 2014 Mar , 19 (237-9).

235

352926

Rodríguez-Ravelo R et al. A K⁺ channel blocking peptide from the Cuban scorpion Rhopalurus garridoi.
Peptides, 2014 Mar , 53 (42-7).

237

352357

239

347671

Pond AL et al. The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve, 2014 Mar , 49 (378-88).

241

344560

242

344422

243

344461

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

247

345375

251

360088

252

360497

Sherhod R et al. Emerging pattern mining to aid toxicological knowledge discovery.
J Chem Inf Model, 2014 Jul 28 , 54 (1864-79).

254

355612

Bando S et al. Congenital long QT syndrome with compound mutations in the KCNH2 gene.
Heart Vessels, 2014 Jul , 29 (554-9).

255

352634

Glengarry JM et al. Long QT molecular autopsy in sudden infant death syndrome.
Arch. Dis. Child., 2014 Jul , 99 (635-40).

257

344169

González Cabrera D et al. 2,4-Diaminothienopyrimidines as Orally Active Antimalarial Agents.
J. Med. Chem., 2014 Jan 28 , ().

258

344135

Radresa O et al. Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen, 2014 Jan 24 , ().

259

341741

Gohlke BO et al. SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res., 2014 Jan 1 , 42 (D1107-12).

261

341427

264

354465

265

353190

268

353370

269

346089

270

346229

Thurner P et al. Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
J. Pharmacol. Exp. Ther., 2014 Feb , 348 (346-58).

272

354824

Ferreiro SF et al. In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.
Arch. Toxicol., 2014 Feb , 88 (425-34).

273

354788

Zhang Y et al. The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.
Pediatr Cardiol, 2014 Feb , 35 (295-300).

274

349991

Roder K et al. RING finger protein RNF207, a novel regulator of cardiac excitation.
J. Biol. Chem., 2014 Dec 5 , 289 (33730-40).

275

358869

Jones DK et al. hERG 1b is critical for human cardiac repolarization.
Proc. Natl. Acad. Sci. U.S.A., 2014 Dec 16 , 111 (18073-7).

277

358875

Lim CJ et al. Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Dec 15 , 24 (5832-5).

281

364417

Strauss KA et al. A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder.
Hum. Mol. Genet., 2014 Dec 1 , 23 (6395-406).

282

359035

283

359417

284

358691

Lin EC et al. Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
J Am Heart Assoc, 2014 Dec , 3 (e001491).

286

359280

287

350166

Li P et al. The human ether-a-go-go-related gene activator NS1643 enhances epilepsy-associated KCNQ channels.
J. Pharmacol. Exp. Ther., 2014 Dec , 351 (596-604).

289

351105

Schmidtke P et al. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
J Chem Inf Model, 2014 Aug 25 , 54 (2320-33).

291

351636

293

350080

294

351539

Hajj A et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration.
Drug Alcohol Depend, 2014 Aug 1 , 141 (34-8).

295

351197

296

353539

297

355927

Liu LL et al. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
Acta Pharmacol. Sin., 2014 Aug , 35 (1093-102).

299

360191

Gong Q et al. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet, 2014 Aug , 7 (482-90).

302

345107

Martinson AS et al. Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr.
Proc. Natl. Acad. Sci. U.S.A., 2014 Apr 15 , 111 (5712-7).

303

352328

Chanséaume A et al. [KCNH2 gene new mutation in a patient with prior diagnosis of epilepsy].
Rev. Neurol. (Paris), 2014 Apr , 170 (304-5).

304

352141

Heijman J et al. Cardiac safety assays.
Curr Opin Pharmacol, 2014 Apr , 15 (16-21).

305

354191

Noriega-Navarro R et al. Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
Neuropharmacology, 2014 Apr , 79 (28-36).

306

353740

Silvestre JS et al. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
J. Psychopharmacol. (Oxford), 2014 Apr , 28 (329-40).

307

352140

Sanguinetti MC HERG1 channel agonists and cardiac arrhythmia.
Curr Opin Pharmacol, 2014 Apr , 15 (22-7).

308

352483

Wu W et al. Stoichiometry of altered hERG1 channel gating by small molecule activators.
J. Gen. Physiol., 2014 Apr , 143 (499-512).

309

345339

Wang D et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci. Int., 2014 Apr , 237 (90-9).

310

344538

Tester DJ et al. GENETICS OF LONG QT SYNDROME.
Methodist Debakey Cardiovasc J, 2014 1 , 10 (29-33).

314

350109

Shao XD et al. The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Bratisl Lek Listy, 2014 , 115 (487-91).

319

345608

Munoz C et al. Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem., 2014 , 33 (491-500).

321

350355

Shimizu W Clinical and genetic diagnosis for inherited cardiac arrhythmias.
J Nippon Med Sch, 2014 , 81 (203-10).

323

355992

325

350183

326

351802

Braga RC et al. Tuning HERG out: antitarget QSAR models for drug development.
Curr Top Med Chem, 2014 , 14 (1399-415).

327

352913

329

353113

Pakladok T et al. Up-regulation of hERG K⁺ channels by B-RAF.
PLoS ONE, 2014 , 9 (e87457).

333

354432

Goodchild SJ et al. Gating charge movement precedes ionic current activation in hERG channels.
Channels (Austin), 2014 , 8 (84-9).

334

350805

Liu J et al. Patch-clamp technique in ESC-derived cardiomyocytes.
Methods Mol. Biol., 2014 , 1181 (203-14).

336

354078

Sanders NG et al. Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Antimicrob. Agents Chemother., 2014 , 58 (820-7).

339

359279

342

360229

344

359800

Zhang K et al. Berberine induces hERG channel deficiency through trafficking inhibition.
Cell. Physiol. Biochem., 2014 , 34 (691-702).

345

359777

Lee SH et al. Blockade of HERG human K+ channels by the antidepressant drug paroxetine.
Biol. Pharm. Bull., 2014 , 37 (1495-504).

346

360228

349

342026

Zeng H et al. Halide Ion Effects on Human Ether-à-go-go Related Gene Potassium Channel Properties.
Assay Drug Dev Technol, 2013 Nov-Dec , 11 (544-50).

351

335392

Morissette P et al. The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (137-49).

352

335375

Elkins RC et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (112-22).

354

348091

Rampe D et al. A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (13-22).

356

355620

Chun YS et al. Cholesterol regulates HERG K+ channel activation by increasing phospholipase C β1 expression.
Channels (Austin), 2013 Jul-Aug , 7 (275-87).

357

343927

358

339515

Haugaa KH et al. Abnormal electroencephalograms in patients with long QT syndrome.
Heart Rhythm, 2013 Sep 27 , ().

359

347066

Czodrowski P hERG me out.
J Chem Inf Model, 2013 Sep 23 , 53 (2240-51).

362

342324

Haitin Y et al. The structural mechanism of KCNH-channel regulation by the eag domain.
Nature, 2013 Sep 19 , 501 (444-8).

363

339578

366

339621

Cordeiro JM et al. Developmental changes in expression and biophysics of ion channels in the canine ventricle.
J. Mol. Cell. Cardiol., 2013 Sep 10 , 64C (79-89).

371

346943

372

346944

373

347947

Nawathe PA et al. An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia.
J. Cardiovasc. Electrophysiol., 2013 Sep , 24 (1021-7).

374

347143

Zhang P et al. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
J. Pharm. Pharmacol., 2013 Sep , 65 (1321-8).

375

347873

Fischer F et al. Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2013 Sep , 386 (795-804).

378

346759

Meng J et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.
Eur. J. Pharmacol., 2013 Oct 15 , 718 (87-97).

381

339946

382

339526

Andreasen L et al. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol, 2013 Oct , 29 (1234-40).

383

342218

Yoshinaga M et al. Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals.
Circ Arrhythm Electrophysiol, 2013 Oct , 6 (932-8).

385

353400

Fiore A et al. Characterization of hERG1 channel role in mouse colorectal carcinogenesis.
Cancer Med, 2013 Oct , 2 (583-94).

386

335415

Salyer SA et al. Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells.
Biochim. Biophys. Acta, 2013 Oct , 1832 (1734-43).

387

346513

Lee YS et al. Long QT syndrome: a Korean single center study.
J. Korean Med. Sci., 2013 Oct , 28 (1454-60).

388

361099

390

354194

392

342289

Stump MR et al. LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.
Am. J. Physiol. Heart Circ. Physiol., 2013 Nov 1 , 305 (H1397-404).

397

347763

Almilaji A et al. AMP-activated protein kinase regulates hERG potassium channel.
Pflugers Arch., 2013 Nov , 465 (1573-82).

398

335887

403

343281

Mitton-Fry MJ et al. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Bioorg. Med. Chem. Lett., 2013 May 15 , 23 (2955-61).

404

335450

Leifert A et al. Differential hERG ion channel activity of ultrasmall gold nanoparticles.
Proc. Natl. Acad. Sci. U.S.A., 2013 May 14 , 110 (8004-9).

405

336264

de la Peña P et al. Mapping of interactions between the N- and C-termini and the channel core in HERG K+ channels.
Biochem. J., 2013 May 1 , 451 (463-74).

411

347765

Aziz PF et al. Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing?
Ann Noninvasive Electrocardiol, 2013 May , 18 (288-93).

415

336630

416

336068

Babcock JJ et al. hERG channel function: beyond long QT.
Acta Pharmacol. Sin., 2013 Mar , 34 (329-35).

417

341326

Hashimoto R et al. The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.
World J. Biol. Psychiatry, 2013 Mar , 14 (114-20).

418

341278

421

335523

Munoz C et al. Klotho sensitivity of the hERG channel.
FEBS Lett., 2013 Jun 5 , 587 (1663-8).

422

334939

Steinke K et al. Coxsackievirus B3 modulates cardiac ion channels.
FASEB J., 2013 Jun 27 , ().

425

341078

Ginman T et al. Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
J. Med. Chem., 2013 Jun 13 , 56 (4181-205).

427

335318

Wang S et al. Recent developments in computational prediction of HERG blockage.
Curr Top Med Chem, 2013 Jun 1 , 13 (1317-26).

429

335137

Townsend C et al. Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures.
Curr Protoc Pharmacol, 2013 Jun , Chapter 10 (Unit10.16).

430

336021

431

335240

432

343368

433

343568

Stowasser M Primary aldosteronism and potassium channel mutations.
Curr Opin Endocrinol Diabetes Obes, 2013 Jun , 20 (170-9).

435

342864

436

348108

Arcangeli A et al. High hERG1 expression in advanced melanoma.
Melanoma Res., 2013 Jun , 23 (185-90).

437

342663

Brelidze TI et al. Structure of the C-terminal region of an ERG channel and functional implications.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jul 9 , 110 (11648-53).

438

334879

Nilsson MF et al. Comparative effects of sodium channel blockers in short term rat whole embryo culture.
Toxicol. Appl. Pharmacol., 2013 Jul 8 , ().

443

342865

Ryu S et al. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Bioorg. Med. Chem. Lett., 2013 Jul 1 , 23 (3848-51).

444

335463

Takanari H et al. Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res., 2013 Jul 1 , 99 (203-14).

445

335594

447

347948

448

347738

Rayan A et al. Indexing molecules for their hERG liability.
Eur J Med Chem, 2013 Jul , 65 (304-14).

451

336873

Di Martino GP et al. An automated docking protocol for hERG channel blockers.
J Chem Inf Model, 2013 Jan 28 , 53 (159-75).

452

336893

453

337560

Di Veroli GY et al. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Am. J. Physiol. Heart Circ. Physiol., 2013 Jan 1 , 304 (H104-17).

455

341140

Narayana Moorthy NS et al. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Curr Drug Targets, 2013 Jan 1 , 14 (102-13).

457

337769

Zarzoso M et al. Mission possible: RNA interference rescues the hERG current.
Heart Rhythm, 2013 Jan , 10 (137-8).

461

339011

Ng CA et al. Insights into hERG K+ channel structure and function from NMR studies.
Eur. Biophys. J., 2013 Jan , 42 (71-9).

462

347860

Wei T et al. [Effect of berberine, liensinine and neferine on HERG channel expression].
Zhongguo Zhong Yao Za Zhi, 2013 Jan , 38 (239-44).

464

331270

465

330413

469

340888

Hausammann GJ et al. Generation of an antibody toolbox to characterize hERG.
Biochem. Biophys. Res. Commun., 2013 Feb 1 , 431 (70-5).

470

340805

Harris RA et al. Human metastable epiallele candidates link to common disorders.
Epigenetics, 2013 Feb , 8 (157-63).

471

343802

Yang LJ et al. New targets for the antitumor activity of gambogic acid in hematologic malignancies.
Acta Pharmacol. Sin., 2013 Feb , 34 (191-8).

472

336610

Gustina AS et al. The eag domain regulates hERG channel inactivation gating via a direct interaction.
J. Gen. Physiol., 2013 Feb , 141 (229-41).

473

337393

Dong H et al. Functional expression of ERG1 potassium channels in rat alveolar macrophages.
J. Mol. Histol., 2013 Feb , 44 (117-24).

474

337390

475

336510

Silva D et al. Novel mutation in the KCNH2 gene associated with long QT syndrome.
Rev Port Cardiol, 2013 Feb , 32 (163-4).

477

346197

Hausammann GJ et al. Chimeric hERG channels containing a tetramerization domain are functional and stable.
Biochemistry, 2013 Dec 23 , 52 (9237-45).

478

341521

Shi YP et al. External protons destabilize the activated voltage sensor in hERG channels.
Eur. Biophys. J., 2013 Dec 21 , ().

480

346366

485

354449

Goineau S et al. In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.
Regul. Toxicol. Pharmacol., 2013 Dec , 67 (499-505).

486

360987

Lin J et al. [Protein tyrosine phosphatase non-receptor type 12 negatively regulates cardiac HERG channel currents].
Nan Fang Yi Ke Da Xue Xue Bao, 2013 Dec , 33 (1718-22).

487

341910

489

339438

490

339774

Hayashi M et al. Molecular basis of potassium channels in pancreatic duct epithelial cells.
Channels (Austin), 2013 Aug 20 , 7 ().

493

347415

Sun H et al. Are hERG channel blockers also phospholipidosis inducers?
Bioorg. Med. Chem. Lett., 2013 Aug 15 , 23 (4587-90).

495

339911

Kruse M et al. The phosphoinositide sensitivity of the KV channel family.
Channels (Austin), 2013 Aug 1 , 7 ().

496

342466

499

348180

501

343573

502

336028

504

335640

Crotti L et al. Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA, 2013 Apr 10 , 309 (1473-82).

505

340475

507

340476

Islas LD The electric heart of hERG.
J. Gen. Physiol., 2013 Apr , 141 (409-11).

509

343665

He FZ et al. Current pharmacogenomic studies on hERG potassium channels.
Trends Mol Med, 2013 Apr , 19 (227-38).

510

340345

Adaixo R et al. Structural properties of PAS domains from the KCNH potassium channels.
PLoS ONE, 2013 , 8 (e59265).

512

339847

Moric-Janiszewska E et al. Quantitative PCR as an Alternative in the Diagnosis of Long-QT Syndrome.
Biomed Res Int, 2013 , 2013 (418604).

513

339749

Ouadid-Ahidouch H et al. K(+) channels and cell cycle progression in tumor cells.
Front Physiol, 2013 , 4 (220).

514

341891

516

342044

Springer C et al. A fingerprint pair analysis of hERG inhibition data.
Chem Cent J, 2013 , 7 (167).

518

336949

519

334965

522

354138

526

353447

Karnik R et al. Endocytosis of HERG is clathrin-independent and involves arf6.
PLoS ONE, 2013 , 8 (e85630).

527

355052

531

347900

Thai KM et al. Pharmacophore modeling for antitargets.
Curr Top Med Chem, 2013 , 13 (1002-14).

532

347110

534

347723

Pakladok T et al. PIKfyve sensitivity of hERG channels.
Cell. Physiol. Biochem., 2013 , 31 (785-94).

537

334272

542

331258

546

329516

548

331167

Zumhagen S et al. Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.
Herzschrittmacherther Elektrophysiol, 2012 Sep , 23 (211-9).

551

331990

Kapoor A et al. Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.
Antimicrob. Agents Chemother., 2012 Sep , 56 (4891-9).

552

332152

553

332946

Bhattarai D et al. Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
Chem Biol Drug Des, 2012 Sep , 80 (388-97).

554

337807

Lee SH et al. Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Arch. Pharm. Res., 2012 Sep , 35 (1655-64).

555

341160

558

331438

Abderemane-Ali F et al. Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem., 2012 Oct 19 , 287 (36158-67).

559

338113

Procopiou PA et al. Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Bioorg. Med. Chem., 2012 Oct 15 , 20 (6097-108).

562

334483

Högberg T et al. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Bioorg. Med. Chem. Lett., 2012 Oct 1 , 22 (6039-47).

565

330769

Lee HA et al. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.
Korean J. Physiol. Pharmacol., 2012 Oct , 16 (327-32).

566

338492

567

334587

569

361144

572

330603

Dong Q et al. Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.
Biol. Pharm. Bull., 2012 Nov 30 , ().

573

337605

Sherhod R et al. Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining.
J Chem Inf Model, 2012 Nov 26 , 52 (3074-87).

574

330683

Portonovo SA et al. hERG drug response measured in droplet bilayers.
Biomed Microdevices, 2012 Nov 18 , ().

576

337920

Bahl A et al. The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bioorg. Med. Chem. Lett., 2012 Nov 1 , 22 (6688-93).

577

339349

Edelmann J et al. Long QT syndrome mutation detection by SNaPshot technique.
Int. J. Legal Med., 2012 Nov , 126 (969-73).

578

338757

580

338526

Kam YL et al. HYP-1, a novel diamide compound, relieves inflammatory and neuropathic pain in rats.
Pharmacol. Biochem. Behav., 2012 Nov , 103 (33-42).

587

348430

Tang H et al. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
ACS Med Chem Lett, 2012 May 10 , 3 (367-72).

589

329946

Jiménez-Vargas JM et al. Interacting sites of scorpion toxin ErgTx1 with hERG1 K+ channels.
Toxicon, 2012 May , 59 (633-41).

590

328952

Boström J et al. Oxadiazoles in medicinal chemistry.
J. Med. Chem., 2012 Mar 8 , 55 (1817-30).

595

328672

Hanrahan P et al. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Bioorg. Med. Chem. Lett., 2012 Mar 15 , 22 (2271-8).

597

328744

Bregman H et al. The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (2033-42).

598

328720

599

328702

Lacombe P et al. 3,4-Diarylpiperidines as potent renin inhibitors.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (1953-7).

600

328859

602

334103

Kaddar N et al. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
J. Cardiovasc. Pharmacol. Ther., 2012 Mar , 17 (102-9).

604

332944

Peterson LB et al. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Mol. Pharm., 2012 Jun 4 , 9 (1841-6).

605

328066

607

332373

Pérez-Victoria I et al. Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica.
J. Nat. Prod., 2012 Jun 22 , 75 (1210-4).

610

332815

Pajouhesh H et al. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Bioorg. Med. Chem. Lett., 2012 Jun 15 , 22 (4153-8).

611

332993

612

333997

Zhao J et al. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
J Ethnopharmacol, 2012 Jun 1 , 141 (685-91).

613

329655

Guo J et al. A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones.
Biochem. Biophys. Res. Commun., 2012 Jun 1 , 422 (305-10).

614

329725

Van Slyke AC et al. Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Am. J. Physiol., Cell Physiol., 2012 Jun , 302 (C1797-806).

620

328011

Gönczi M et al. Age-dependent changes in ion channel mRNA expression in canine cardiac tissues.
Gen. Physiol. Biophys., 2012 Jun , 31 (153-62).

622

338936

De Conti L et al. Complexities of 5'splice site definition: implications in clinical analyses.
RNA Biol, 2012 Jun , 9 (911-23).

623

332116

Kulzer M et al. Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.
Biochem. Biophys. Res. Commun., 2012 Jul 27 , 424 (315-20).

624

328077

625

332937

Hayashi M et al. An intermediate-conductance Ca2+-activated K+ channel is important for secretion in pancreatic duct cells.
Am. J. Physiol., Cell Physiol., 2012 Jul 15 , 303 (C151-9).

630

331212

Vandenberg JI et al. hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev., 2012 Jul , 92 (1393-478).

635

327633

Sroubek J et al. The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.
J. Immunol. Methods, 2012 Jan 31 , 375 (215-22).

637

325256

Hu CW et al. Curcumin inhibits hERG potassium channels in vitro.
Toxicol. Lett., 2012 Jan 25 , 208 (192-6).

639

330078

McCauley JP et al. Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1169-73).

640

323814

Nguyen HN et al. Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1055-60).

642

330103

Sundar BG et al. Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 1 , 22 (120-3).

644

327739

Krishnan Y et al. Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.
Pacing Clin Electrophysiol, 2012 Jan , 35 (3-16).

646

329225

Huang X et al. Comparative effects of Guanfu base A and Guanfu base G on HERG K+ channel.
J. Cardiovasc. Pharmacol., 2012 Jan , 59 (77-83).

647

327094

El Harchi A et al. Molecular determinants of hERG potassium channel inhibition by disopyramide.
J. Mol. Cell. Cardiol., 2012 Jan , 52 (185-95).

650

326470

Yamakawa Y et al. Pharmacophore modeling for hERG channel facilitation.
Biochem. Biophys. Res. Commun., 2012 Feb 3 , 418 (161-6).

658

327074

Dennis AT et al. Molecular determinants of pentamidine-induced hERG trafficking inhibition.
Mol. Pharmacol., 2012 Feb , 81 (198-209).

660

337614

Baaklini I et al. The DNAJA2 substrate release mechanism is essential for chaperone-mediated folding.
J. Biol. Chem., 2012 Dec 7 , 287 (41939-54).

661

337558

663

337150

González Cabrera D et al. Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines.
J. Med. Chem., 2012 Dec 27 , 55 (11022-30).

664

330447

Schweikart K et al. The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro, 2012 Dec 20 , 27 (745-751).

665

330668

Ishii K et al. Endocytic regulation of voltage-dependent potassium channels in the heart.
J. Pharmacol. Sci., 2012 Dec 18 , 120 (264-9).

666

330485

Organ-Darling LE et al. Interactions between hERG and KCNQ1 α-subunits are mediated by their C-termini and modulated by cAMP.
Am. J. Physiol. Heart Circ. Physiol., 2012 Dec 15 , ().

668

337435

Tanis VM et al. Azabenzthiazole inhibitors of leukotriene A₄ hydrolase.
Bioorg. Med. Chem. Lett., 2012 Dec 15 , 22 (7504-11).

670

334347

Warner B Genetic variation in KCNH2 and a unique hERG isoform in patients with schizophrenia: efficacy-safety link.
Am J Psychiatry, 2012 Dec 1 , 169 (1318; author reply 1318-9).

671

330728

673

337869

674

338988

Peters MF et al. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Assay Drug Dev Technol, 2012 Dec , 10 (525-32).

676

331975

Butini S et al. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
J. Med. Chem., 2012 Aug 9 , 55 (6898-915).

678

332788

Liu Y et al. Effects of the natural flavone trimethylapigenin on cardiac potassium currents.
Biochem. Pharmacol., 2012 Aug 15 , 84 (498-506).

679

329517

Twiner MJ et al. Marine Algal Toxin Azaspiracid Is an Open-State Blocker of hERG Potassium Channels.
Chem. Res. Toxicol., 2012 Aug 10 , ().

682

333682

683

329529

Kruse M et al. Regulation of voltage-gated potassium channels by PI(4,5)P2.
J. Gen. Physiol., 2012 Aug , 140 (189-205).

685

348432

Gustina AS et al. HERG potassium channel regulation by the N-terminal eag domain.
Cell. Signal., 2012 Aug , 24 (1592-8).

686

334695

687

338944

Krishnan Y et al. Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis.
Biochim. Biophys. Acta, 2012 Aug , 1823 (1273-84).

688

326400

Jiménez-Vargas JM et al. Toxin modulators and blockers of hERG K(+) channels.
, 2012 Apr 5 , ().

690

328415

Cavalli A et al. Computational design and discovery of "minimally structured" hERG blockers.
J. Med. Chem., 2012 Apr 26 , 55 (4010-4).

693

326668

697

328566

699

326917

Ababneh D et al. Antidepressants Cause Bradycardia and Heart Block in GD 13 Rat Embryos In Vitro.
Birth Defects Res. B Dev. Reprod. Toxicol., 2012 Apr , 95 (184-93).

700

329206

702

333435

703

330155

705

330742

Ceccarini L et al. Ion conduction through the hERG potassium channel.
PLoS ONE, 2012 , 7 (e49017).

706

331096

707

331255

708

331260

Moreno C et al. Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol, 2012 , 3 (163).

715

327265

Cheng YM et al. Voltage-dependent gating of HERG potassium channels.
Front Pharmacol, 2012 , 3 (83).

719

338568

Ferro F et al. Long-chain acylcarnitines regulate the hERG channel.
PLoS ONE, 2012 , 7 (e41686).

720

338575

Köpfer DA et al. A molecular switch driving inactivation in the cardiac K+ channel HERG.
PLoS ONE, 2012 , 7 (e41023).

721

336998

722

337063

Lazarczyk MJ et al. Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.
BMC Psychiatry, 2012 , 12 (220).

724

338407

Munoz C et al. Stimulation of HERG channel activity by β-catenin.
PLoS ONE, 2012 , 7 (e43353).

725

336819

726

334554

727

339103

Moric-Janiszewska E et al. Molecular diagnostics of families with long-QT syndrome.
Cardiol J, 2012 , 19 (159-67).

731

368031

Zhang GH et al. Cytocompatible performance of thermosensitive poly(N-isopropylacrylamide) nanoparticles.
J Biomater Sci Polym Ed, 2012 , 23 (1569-78).

732

329251

Qu Y et al. hERG potency estimates based upon dose solution analysis: What have we learned?
J Pharmacol Toxicol Methods, 2011 Nov-Dec , 64 (251-7).

733

320233

Champeroux P et al. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
J Pharmacol Toxicol Methods, 2011 May-Jun , 63 (269-78).

734

320161

735

318054

736

323147

Dennis AT et al. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
J. Biol. Chem., 2011 Sep 30 , 286 (34413-25).

737

323252

739

325921

Abi-Gerges N et al. hERG subunit composition determines differential drug sensitivity.
Br. J. Pharmacol., 2011 Sep , 164 (419-32).

745

324739

752

325069

Jeon SH et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study.
Hum Exp Toxicol, 2011 Oct , 30 (1649-56).

754

324877

757

322996

Tester DJ et al. Unexplained drownings and the cardiac channelopathies: a molecular autopsy series.
Mayo Clin. Proc., 2011 Oct , 86 (941-7).

758

320404

Wang RR et al. The effects of paeoniflorin monomer of a Chinese herb on cardiac ion channels.
Chin. Med. J., 2011 Oct , 124 (3105-11).

762

326262

765

320431

766

320720

768

323882

Furutani K et al. A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Biochem. Biophys. Res. Commun., 2011 Nov 11 , 415 (141-6).

769

324707

González Cabrera D et al. Novel orally active antimalarial thiazoles.
J. Med. Chem., 2011 Nov 10 , 54 (7713-9).

772

324891

Bai YL et al. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
J. Mol. Cell. Cardiol., 2011 Nov , 51 (876-80).

776

319780

Wiles JA et al. Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
J. Med. Chem., 2011 May 12 , 54 (3418-25).

778

319394

Xia M et al. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Toxicol. Appl. Pharmacol., 2011 May 1 , 252 (250-8).

780

322002

Ando F et al. Synergic effects of β-estradiol and erythromycin on hERG currents.
J. Membr. Biol., 2011 May , 241 (31-8).

781

322499

Soma K et al. Abundant expression of KCNE1 in the left ventricle of the miniature pig.
Heart Vessels, 2011 May , 26 (353-6).

782

319357

Schramm A et al. HERG channel inhibitors in extracts of Coptidis rhizoma.
Planta Med., 2011 May , 77 (692-7).

784

318324

786

318185

Luker T et al. Zwitterionic CRTh2 antagonists.
J. Med. Chem., 2011 Mar 24 , 54 (1779-88).

789

318525

790

317371

Gustina AS et al. hERG potassium channel gating is mediated by N- and C-terminal region interactions.
J. Gen. Physiol., 2011 Mar , 137 (315-25).

791

318536

Sun Y et al. A novel mutation in the KCNH2 gene associated with short QT syndrome.
J. Mol. Cell. Cardiol., 2011 Mar , 50 (433-41).

794

319556

796

321949

798

320037

805

323496

Liu Y et al. The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.
Bioorg. Med. Chem. Lett., 2011 Jun 15 , 21 (3712-4).

806

321867

807

355341

808

321510

Zhou PZ et al. Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.
Acta Pharmacol. Sin., 2011 Jun , 32 (781-8).

809

322176

Vigneault P et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
J. Cardiovasc. Pharmacol., 2011 Jun , 57 (690-5).

810

319420

Choi KH et al. hERG channel blockade by externally applied quaternary ammonium derivatives.
Biochim. Biophys. Acta, 2011 Jun , 1808 (1560-6).

812

321969

Johansson A Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists.
Expert Opin Ther Pat, 2011 Jun , 21 (905-25).

815

319213

Tang G et al. Identification of a Novel Bacterial K(+) Channel.
, 2011 Jul 9 , ().

820

321378

Boukharta L et al. Computer simulations of structure-activity relationships for HERG channel blockers.
Biochemistry, 2011 Jul 12 , 50 (6146-56).

823

323604

Couderc JP et al. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Heart Rhythm, 2011 Jul , 8 (1036-43).

826

314307

827

316240

829

314092

831

314113

832

316058

834

316350

Han S et al. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Eur. J. Pharmacol., 2011 Jan 10 , 650 (138-44).

838

314554

839

318709

840

314348

Stump MR et al. Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol., 2011 Jan , 300 (H312-8).

848

316577

Du CY et al. Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform.
Biochem. Biophys. Res. Commun., 2011 Feb 11 , 405 (222-7).

851

315586

Hu C et al. Down-regulation of the human ether-a-go-go-related gene in rat cardiac hypertrophy.
Am. J. Med. Sci., 2011 Feb , 341 (119-25).

852

317474

Staudacher I et al. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Naunyn Schmiedebergs Arch. Pharmacol., 2011 Feb , 383 (119-39).

854

319597

Zhu S et al. Molecular diversity and functional evolution of scorpion potassium channel toxins.
Mol. Cell Proteomics, 2011 Feb , 10 (M110.002832).

855

325518

Bentzen BH et al. Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol., 2011 Feb , 57 (223-30).

856

323830

860

325776

Brocklehurst KJ et al. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Bioorg. Med. Chem. Lett., 2011 Dec 15 , 21 (7310-6).

864

327117

Chen J et al. A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L.
Pacing Clin Electrophysiol, 2011 Dec , 34 (1652-64).

866

327003

868

327156

Sung RK et al. QTc prolongation and family history of sudden death in a patient with desmin cardiomyopathy.
Pacing Clin Electrophysiol, 2011 Dec , 34 (e105-8).

870

339269

Shao C et al. Electrophysiological study of V535M hERG mutation of LQT2.
J. Huazhong Univ. Sci. Technol. Med. Sci., 2011 Dec , 31 (741-8).

871

323218

Bett GC et al. Models of HERG gating.
Biophys. J., 2011 Aug 3 , 101 (631-42).

872

323216

Es-Salah-Lamoureux Z et al. Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant.
Biophys. J., 2011 Aug 3 , 101 (662-70).

873

320986

Giustetto C et al. Long-term follow-up of patients with short QT syndrome.
J. Am. Coll. Cardiol., 2011 Aug 2 , 58 (587-95).

874

323300

Park SJ et al. Bioactive sulfoximines: syntheses and properties of Vioxx analogs.
Bioorg. Med. Chem. Lett., 2011 Aug 15 , 21 (4888-90).

876

323489

879

322591

Witchel HJ Drug-induced hERG block and long QT syndrome.
Cardiovasc Ther, 2011 Aug , 29 (251-9).

880

323720

Du D et al. Multi-scale modeling of glycosylation modulation dynamics in cardiac electrical signaling.
Conf Proc IEEE Eng Med Biol Soc, 2011 Aug , 2011 (104-7).

886

319354

Fox BM et al. Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
Bioorg. Med. Chem. Lett., 2011 Apr 15 , 21 (2460-7).

889

319547

El Gebeily G et al. Upregulation of ventricular potassium channels by chronic tamoxifen treatment.
Cardiovasc. Res., 2011 Apr 1 , 90 (68-76).

890

319527

Windisch A et al. Trapping and dissociation of propafenone derivatives in HERG channels.
Br. J. Pharmacol., 2011 Apr , 162 (1542-52).

891

321958

892

321957

Grilo LS et al. Patient with syncope and LQTS carrying a mutation in the PAS domain of the hERG1 channel.
Ann Noninvasive Electrocardiol, 2011 Apr , 16 (213-8).

895

314104

Lahtinen AM et al. KCNE1 D85N polymorphism - a sex-specific modifier in type 1 long QT syndrome?
BMC Med. Genet., 2011 , 12 (11).

896

317963

897

314409

Chen XL et al. Manual whole-cell patch-clamping of the HERG cardiac K+ channel.
Methods Mol. Biol., 2011 , 691 (151-63).

902

319983

Jehle J et al. Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
Cell Death Dis, 2011 , 2 (e193).

904

322783

905

320405

Frolov RV et al. Inhibition of HERG potassium channels by celecoxib and its mechanism.
PLoS ONE, 2011 , 6 (e26344).

911

326212

Yun J et al. Hirsutenone directly blocks human ether-a-go-go related gene K+ channels.
Biol. Pharm. Bull., 2011 , 34 (1815-22).

918

137672

919

141934

Himmel HM et al. QTc shortening with a new investigational cancer drug: a brief case study.
J Pharmacol Toxicol Methods, 2010 Jul-Aug , 62 (72-81).

920

322669

Wilders R et al. Role of the R1135H KCNH2 mutation in Brugada syndrome.
Int. J. Cardiol., 2010 Sep 24 , 144 (149-51).

921

322671

Yasuda S et al. A family of hereditary long QT syndrome caused by Q738X HERG mutation.
Int. J. Cardiol., 2010 Sep 24 , 144 (69-72).

924

318763

Perry M et al. Revealing the structural basis of action of hERG potassium channel activators and blockers.
J. Physiol. (Lond.), 2010 Sep 1 , 588 (3157-67).

925

314963

Bokil NJ et al. Molecular genetics of long QT syndrome.
Mol. Genet. Metab., 2010 Sep , 101 (1-8).

926

139260

Mathie A Ion channels as novel therapeutic targets in the treatment of pain.
J. Pharm. Pharmacol., 2010 Sep , 62 (1089-95).

927

142161

Zünkler BJ et al. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
Cardiovasc. Toxicol., 2010 Sep , 10 (161-5).

928

140339

Lazzerini PE et al. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses.
Scand. J. Immunol., 2010 Sep , 72 (213-22).

933

141615

935

315652

Liu Y et al. 9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.
Bioorg. Med. Chem. Lett., 2010 Oct 1 , 20 (5658-61).

938

314976

Larsen AP Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.
Pflugers Arch., 2010 Oct , 460 (803-12).

939

314546

Larsen AP et al. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.
Br. J. Pharmacol., 2010 Oct , 161 (614-28).

940

314755

Jeong I et al. Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.
Pflugers Arch., 2010 Oct , 460 (851-62).

941

314716

Hondeghem LM et al. Oscillations of cardiac wave length and proarrhythmia.
Naunyn Schmiedebergs Arch. Pharmacol., 2010 Oct , 382 (367-76).

942

316114

Du CY et al. Acidosis impairs the protective role of hERG K(+) channels against premature stimulation.
J. Cardiovasc. Electrophysiol., 2010 Oct , 21 (1160-9).

944

140425

Abela D et al. The effect of drugs with ion channel-blocking activity on the early embryonic rat heart.
Birth Defects Res. B Dev. Reprod. Toxicol., 2010 Oct , 89 (429-40).

947

138329

Sordel T et al. The development of high quality seals for silicon patch-clamp chips.
Biomaterials, 2010 Oct , 31 (7398-410).

950

314367

Van Slyke AC et al. Mutations within the S4-S5 linker alter voltage sensor constraints in hERG K+ channels.
Biophys. J., 2010 Nov 3 , 99 (2841-52).

953

316492

Pryde DC et al. An in situ oxidation strategy towards overcoming hERG affinity.
Bioorg. Med. Chem. Lett., 2010 Nov 15 , 20 (6400-4).

954

314649

Anderson JT et al. Investigation of 4-piperidinols as novel H3 antagonists.
Bioorg. Med. Chem. Lett., 2010 Nov 1 , 20 (6246-9).

955

314633

Rankovic Z et al. Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.
Bioorg. Med. Chem. Lett., 2010 Nov 1 , 20 (6237-41).

958

316112

Sy RW et al. Repolarization dynamics during exercise discriminate between LQT1 and LQT2 genotypes.
J. Cardiovasc. Electrophysiol., 2010 Nov , 21 (1242-6).

965

137011

967

138616

Gu SJ et al. Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett., 2010 May 1 , 20 (2705-8).

968

139337

Allegue C et al. A new approach to long QT syndrome mutation detection by Sequenom MassARRAY system.
Electrophoresis, 2010 May , 31 (1648-55).

969

139824

Kim KS et al. Blockade of hERG K(+) channel by antimalarial drug, primaquine.
Arch. Pharm. Res., 2010 May , 33 (769-73).

970

138721

971

322826

Möller C Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
Expert Rev Clin Pharmacol, 2010 May , 3 (321-9).

972

124980

975

137828

Xing J et al. Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Eur. J. Pharmacol., 2010 Mar 25 , 630 (1-9).

976

137735

Stary A et al. Toward a consensus model of the HERG potassium channel.
ChemMedChem, 2010 Mar 1 , 5 (455-67).

977

136555

983

137942

Amit G et al. Selective molecular potassium channel blockade prevents atrial fibrillation.
Circulation, 2010 Jun 1 , 121 (2263-70).

985

137961

Lin EC et al. Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes.
Am. J. Physiol. Heart Circ. Physiol., 2010 Jun , 298 (H1842-9).

986

137959

Zhou Q et al. Regulation of the voltage-insensitive step of HERG activation by extracellular pH.
Am. J. Physiol. Heart Circ. Physiol., 2010 Jun , 298 (H1710-8).

987

140117

Gong JH et al. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells.
Oncol. Rep., 2010 Jun , 23 (1747-56).

993

138239

Weerakoon P et al. Patch-clamp amplifiers on a chip.
, 2010 Jul 15 , ().

995

138237

van Noord C et al. Drug- and non-drug-associated QT interval prolongation.
Br J Clin Pharmacol, 2010 Jul , 70 (16-23).

996

139592

Sanguinetti MC HERG1 channelopathies.
Pflugers Arch., 2010 Jul , 460 (265-76).

997

138632

Ganapathi SB et al. Ceramide modulates HERG potassium channel gating by translocation into lipid rafts.
Am. J. Physiol., Cell Physiol., 2010 Jul , 299 (C74-86).

998

142445

999

314912

Testai L et al. Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs.
J. Pharm. Pharmacol., 2010 Jul , 62 (924-30).

1000

124779

Walker VE et al. Hsp40 chaperones promote degradation of the HERG potassium channel.
J. Biol. Chem., 2010 Jan 29 , 285 (3319-29).

1003

137285

Kallander LS et al. Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Bioorg. Med. Chem. Lett., 2010 Jan 1 , 20 (371-4).

1004

137290

Martyn DC et al. Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.
Bioorg. Med. Chem. Lett., 2010 Jan 1 , 20 (228-31).

1005

125018

Bagnes C et al. Antineoplastic Chemotherapy Induced QTc Prolongation.
Curr Drug Saf, 2010 Jan 1 , 5 (93-6).

1006

125019

Ponte ML et al. Mechanisms of Drug Induced QT Interval Prolongation.
Curr Drug Saf, 2010 Jan 1 , 5 (44-53).

1007

124847

Ramström C et al. Regulation of HERG (KCNH2) potassium channel surface expression by diacylglycerol.
Cell. Mol. Life Sci., 2010 Jan , 67 (157-69).

1008

124719

Staudacher I et al. hERG: protein trafficking and potential for therapy and drug side effects.
Curr Opin Drug Discov Devel, 2010 Jan , 13 (23-30).

1009

125748

Dolderer JH et al. HERG1 gene expression as a specific tumor marker in colorectal tissues.
Eur J Surg Oncol, 2010 Jan , 36 (72-7).

1011

136794

Charpentier F et al. Delayed rectifier K(+) currents and cardiac repolarization.
J. Mol. Cell. Cardiol., 2010 Jan , 48 (37-44).

1012

136716

1013

136717

1014

136777

1015

136791

1017

137627

Alvarez PA et al. QT alterations in psychopharmacology: proven candidates and suspects.
Curr Drug Saf, 2010 Jan , 5 (97-104).

1018

137626

Keller GA et al. Other drugs acting on nervous system associated with QT-interval prolongation.
Curr Drug Saf, 2010 Jan , 5 (105-11).

1021

122899

1023

136139

Nugiel DA et al. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
J. Med. Chem., 2010 Feb 25 , 53 (1876-80).

1028

137143

Lian J et al. [A novel mutation of the KCNH2 gene in a family with congenital long QT syndrome]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2010 Feb , 27 (77-80).

1029

136457

Carrisoza R et al. Expression and immunolocalization of ERG1 potassium channels in the rat kidney.
Histochem. Cell Biol., 2010 Feb , 133 (189-99).

1030

314354

Li Q et al. NMR solution structure of the N-terminal domain of hERG and its interaction with the S4-S5 linker.
Biochem. Biophys. Res. Commun., 2010 Dec 3 , 403 (126-32).

1032

141040

1036

315596

1038

315607

Surman MD et al. 5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Bioorg. Med. Chem. Lett., 2010 Dec 1 , 20 (7015-9).

1039

315599

Thewlis KM et al. N-substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators.
Bioorg. Med. Chem. Lett., 2010 Dec 1 , 20 (7116-9).

1041

141169

Cao X et al. Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system.
Assay Drug Dev Technol, 2010 Dec , 8 (766-80).

1045

319627

Oshiro C et al. KCNH2 pharmacogenomics summary.
Pharmacogenet. Genomics, 2010 Dec , 20 (775-7).

1046

334101

Zhang XM et al. [Chinfloxacin hydrochloride inhibits HERG potassium channel at open state].
Yao Xue Xue Bao, 2010 Dec , 45 (1491-6).

1048

318759

1049

317006

Kim JA et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2.
Heart Rhythm, 2010 Dec , 7 (1797-805).

1053

139379

Zhang T et al. LQTS gene LOVD database.
, 2010 Aug 31 , ().

1057

138341

Li Y et al. Aconitine blocks HERG and Kv1.5 potassium channels.
, 2010 Aug 19 , 131 (187-195).

1058

141567

Vandenberg JI Oxidative stress fine-tunes the dance of hERG K+ channels.
J. Physiol. (Lond.), 2010 Aug 15 , 588 (2975).

1059

141997

Kolbe K et al. Cysteine 723 in the C-linker segment confers oxidative inhibition of hERG1 potassium channels.
J. Physiol. (Lond.), 2010 Aug 15 , 588 (2999-3009).

1064

142411

1065

142705

Larsen AP et al. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
J. Cardiovasc. Electrophysiol., 2010 Aug 1 , 21 (923-9).

1067

140381

Stead LF et al. KvDB; mining and mapping sequence variants in voltage-gated potassium channels.
Hum. Mutat., 2010 Aug , 31 (908-17).

1068

140751

Abbruzzese J et al. Modification of hERG1 channel gating by Cd2+.
J. Gen. Physiol., 2010 Aug , 136 (203-24).

1070

137090

Hong HK et al. Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Biochem. Biophys. Res. Commun., 2010 Apr 9 , 394 (536-41).

1071

138850

Gessner G et al. The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.
Eur. J. Pharmacol., 2010 Apr 25 , 632 (52-9).

1074

136847

1075

137212

Wong JA et al. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome.
Circ Arrhythm Electrophysiol, 2010 Apr 1 , 3 (120-5).

1077

137674

Gladding PA et al. Posthumous diagnosis of long QT syndrome from neonatal screening cards.
Heart Rhythm, 2010 Apr , 7 (481-6).

1079

136355

Ding XW et al. Prognostic significance of hERG1 expression in gastric cancer.
Dig. Dis. Sci., 2010 Apr , 55 (1004-10).

1082

137982

Friemel A et al. Interactions at human ether-à-go-go-related gene channels.
Toxicol. Sci., 2010 Apr , 114 (346-55).

1083

138781

1084

140157

1085

139149

Kise H et al. Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog.
Basic Clin. Pharmacol. Toxicol., 2010 Apr , 106 (288-95).

1086

140897

Kotta CM et al. Cardiac ion channel gene mutations in Greek long QT syndrome patients.
J. Appl. Genet., 2010 , 51 (515-8).

1089

140941

1093

318531

1094

314266

1096

315748

Hu MQ et al. The novel mechanism of oxymatrine affecting HERG currents at different temperatures.
Cell. Physiol. Biochem., 2010 , 26 (513-22).

1097

124157

Tabrizchi R Molecular mechanisms of adverse drug reactions in cardiac tissue.
Handb Exp Pharmacol, 2010 , (77-109).

1099

137365

Pillozzi S et al. Physical and functional interaction between integrins and hERG1 channels in cancer cells.
Adv. Exp. Med. Biol., 2010 , 674 (55-67).

1100

137366

Masi A et al. Optical methods in the study of protein-protein interactions.
Adv. Exp. Med. Biol., 2010 , 674 (33-42).

1102

123859

1103

6832

Lee HA et al. Cellular mechanism of the QT prolongation induced by sulpiride.
Int. J. Toxicol., 2009 May-Jun , 28 (207-12).

1104

123271

Markert M et al. Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing.
J Pharmacol Toxicol Methods, 2009 Jul-Aug , 60 (79-87).

1105

122197

Mo ZL et al. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.
J Pharmacol Toxicol Methods, 2009 Jul-Aug , 60 (39-44).

1106

122998

Towart R et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
J Pharmacol Toxicol Methods, 2009 Jul-Aug , 60 (1-10).

1108

121912

1111

136918

Itoh H et al. A novel KCNH2 mutation as a modifier for short QT interval.
Int. J. Cardiol., 2009 Sep 11 , 137 (83-5).

1112

121774

1114

123275

1115

122516

Wu L et al. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Am. J. Physiol. Heart Circ. Physiol., 2009 Sep , 297 (H1048-57).

1116

123454

Raschi E et al. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
Expert Opin Drug Metab Toxicol, 2009 Sep , 5 (1005-21).

1119

131403

Robertson GA Endocytic control of ion channel density as a target for cardiovascular disease.
J. Clin. Invest., 2009 Sep , 119 (2531-4).

1121

122807

Lacerda AE et al. Vanoxerine: Cellular Mechanism of a New Antiarrhythmic.
J. Cardiovasc. Electrophysiol., 2009 Oct 8 , ().

1122

122861

Ponte ML et al. Mechanisms of Drug Induced QT Interval Prolongation.
, 2009 Oct 7 , ().

1123

122987

Bagnes C et al. Antineoplastic Chemotherapy Induced QTc Prolongation.
, 2009 Oct 7 , ().

1124

120937

Hardy AB et al. Characterization of Erg K+ channels in alpha- and beta-cells of mouse and human islets.
J. Biol. Chem., 2009 Oct 30 , 284 (30441-52).

1125

120997

Nanduri J et al. Hypoxia inhibits maturation and trafficking of hERG K(+) channel protein: Role of Hsp90 and ROS.
Biochem. Biophys. Res. Commun., 2009 Oct 16 , 388 (212-6).

1129

123658

Wang QS et al. Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese.
J. Cardiovasc. Electrophysiol., 2009 Oct , 20 (1158-62).

1131

121297

Itoh H et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome.
Circ Arrhythm Electrophysiol, 2009 Oct , 2 (511-23).

1133

334157

Cui G et al. Effect of Gambogic acid on the regulation of hERG channel in K562 cells in vitro.
J. Huazhong Univ. Sci. Technol. Med. Sci., 2009 Oct , 29 (540-5).

1134

131322

1135

122622

Perry M et al. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
Proc. Natl. Acad. Sci. U.S.A., 2009 Nov 24 , 106 (20075-80).

1136

131296

Shimizu W et al. Genotype-phenotype aspects of type 2 long QT syndrome.
J. Am. Coll. Cardiol., 2009 Nov 24 , 54 (2052-62).

1137

121390

Zamponi GW et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers.
Bioorg. Med. Chem. Lett., 2009 Nov 15 , 19 (6467-72).

1140

123605

Jo SH et al. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Pharmacol. Res., 2009 Nov , 60 (429-37).

1141

120850

Hirdes W et al. Erg K+ currents modulate excitability in mouse mitral/tufted neurons.
Pflugers Arch., 2009 Nov , 459 (55-70).

1146

9804

Karczewski J et al. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Biochem. Pharmacol., 2009 May 15 , 77 (1602-11).

1147

131706

1149

123039

Wiśniowska B et al. hERG in vitro interchange factors--development and verification.
Toxicol. Mech. Methods, 2009 May , 19 (278-84).

1153

131768

Chen J et al. PKA phosphorylation of HERG protein regulates the rate of channel synthesis.
Am. J. Physiol. Heart Circ. Physiol., 2009 May , 296 (H1244-54).

1154

131735

Abbott GW et al. HERG biosynthesis: the positive influence of negative charge.
Am. J. Physiol. Heart Circ. Physiol., 2009 May , 296 (H1211-2).

1156

322652

Dearden JC Conference Report: update on ADMET.
Future Med Chem, 2009 May , 1 (249-51).

1158

9034

Pages G et al. Structure of the pore-helix of the hERG K(+) channel.
Eur. Biophys. J., 2009 Mar 21 , ().

1159

4313

Owen DR et al. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Bioorg. Med. Chem. Lett., 2009 Mar 15 , 19 (1702-6).

1160

3710

Barber CG et al. 1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: Part 2.
Bioorg. Med. Chem. Lett., 2009 Mar 1 , 19 (1499-503).

1163

388

Cavero I et al. Safety Pharmacology Society: 8th annual meeting.
, 2009 Mar , 8 (237-47).

1164

1321

Salama G et al. Arrhythmia phenotype in mouse models of human long QT.
, 2009 Mar , 24 (77-87).

1165

125857

1166

5550

Zaks-Makhina E et al. Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid.
J. Biol. Chem., 2009 Jun 5 , 284 (15432-8).

1167

2254

Ureche ON et al. Differential modulation of cardiac potassium channels by Grb adaptor proteins.
Biochem. Biophys. Res. Commun., 2009 Jun 19 , 384 (28-31).

1169

123035

1170

120646

Stepanovic SZ et al. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
J. Physiol. (Lond.), 2009 Jun 1 , 587 (2555-66).

1172

131684

1173

120527

1174

6349

Chen MX et al. In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk.
Curr. Opin. Mol. Ther., 2009 Jun , 11 (269-81).

1177

121555

1178

3594

Al-Owais M et al. Role of intracellular domains in the function of the herg potassium channel.
Eur. Biophys. J., 2009 Jun , 38 (569-76).

1184

122863

Kobayashi K et al. Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.
Bioorg. Med. Chem. Lett., 2009 Jul 1 , 19 (3627-31).

1186

8366

1187

122172

1189

322640

Hamon J et al. In vitro safety pharmacology profiling: what else beyond hERG?
Future Med Chem, 2009 Jul , 1 (645-65).

1190

3346

1194

131877

1195

123111

Pedroso N et al. Modulation of plasma membrane lipid profile and microdomains by H2O2 in Saccharomyces cerevisiae.
Free Radic. Biol. Med., 2009 Jan 15 , 46 (289-98).

1196

3177

Scherer D et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.
Br. J. Pharmacol., 2009 Jan , 156 (226-36).

1198

7339

Farre C et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology.
Comb. Chem. High Throughput Screen., 2009 Jan , 12 (24-37).

1199

121062

Kim KS et al. Effect of sibutramine HCl on cardiac hERG K+ channel.
Mol. Cell. Biochem., 2009 Jan , 320 (125-31).

1200

9448

Kakusaka S et al. A receptor-independent effect of estrone sulfate on the HERG channel.
J. Pharmacol. Sci., 2009 Jan , 109 (152-6).

1201

8511

Barber CG et al. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
Bioorg. Med. Chem. Lett., 2009 Feb 15 , 19 (1075-9).

1202

1338

1205

8715

1212

124628

Shi RM et al. [Gene mutation analysis of a Chinese family of congenital long Q-T syndrome type three.]
Zhonghua Er Ke Za Zhi, 2009 Dec , 47 (926-30).

1213

122224

Elliott DJ et al. Movement of the S4 segment in the hERG potassium channel during membrane depolarization.
Mol. Membr. Biol., 2009 Dec , 26 (435-47).

1214

122545

Fenu LA et al. Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay.
J. Comput. Aided Mol. Des., 2009 Dec , 23 (883-95).

1215

124358

Wulff H et al. Voltage-gated potassium channels as therapeutic targets.
Nat Rev Drug Discov, 2009 Dec , 8 (982-1001).

1216

121244

Hong HK et al. Inhibition of the human ether-a-go-go-related gene (HERG) K+ channels by Lindera erythrocarpa.
J. Korean Med. Sci., 2009 Dec , 24 (1089-98).

1218

136403

Iturralde-Torres P et al. [Genetic in long QT syndromes]
Arch Cardiol Mex, 2009 Dec , 79 Suppl 2 (26-30).

1220

123424

1221

131442

Nishio Y et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome.
J. Am. Coll. Cardiol., 2009 Aug 25 , 54 (812-9).

1223

123860

1224

122161

1226

121273

Washburn DG et al. Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.
Bioorg. Med. Chem. Lett., 2009 Aug 15 , 19 (4664-8).

1227

120560

McPate MJ et al. hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome.
Biochem. Biophys. Res. Commun., 2009 Aug 14 , 386 (111-7).

1230

123800

1232

121944

Coon T et al. Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
Bioorg. Med. Chem. Lett., 2009 Aug 1 , 19 (4380-4).

1234

122997

Gu DF et al. Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells.
Naunyn Schmiedebergs Arch. Pharmacol., 2009 Aug , 380 (143-51).

1235

122361

1236

123683

1237

121462

Einarsen K et al. Functional properties of human neuronal Kv11 channels.
Pflugers Arch., 2009 Aug , 458 (689-700).

1238

121789

1240

138149

1241

6475

Scholz EP et al. Biophysical properties of zebrafish ether-à-go-go related gene potassium channels.
Biochem. Biophys. Res. Commun., 2009 Apr 3 , 381 (159-64).

1246

2117

Su Z et al. Electrophysiologic characterization of a novel hERG channel activator.
Biochem. Pharmacol., 2009 Apr 15 , 77 (1383-90).

1247

6698

Zhao XL et al. Comparative effects of sophocarpine and sophoridine on hERG K+ channel.
Eur. J. Pharmacol., 2009 Apr 1 , 607 (15-22).

1248

7603

Ganapathi SB et al. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Am. J. Physiol., Cell Physiol., 2009 Apr , 296 (C701-10).

1251

6249

1253

9364

1254

122728

1256

131721

Newton-Cheh C et al. Common variants at ten loci influence QT interval duration in the QTGEN Study.
Nat. Genet., 2009 Apr , 41 (399-406).

1257

131720

Pfeufer A et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study.
Nat. Genet., 2009 Apr , 41 (407-14).

1259

6048

Hutter MC In silico prediction of drug properties.
Curr. Med. Chem., 2009 , 16 (189-202).

1260

3748

Mruk K et al. Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes.
PLoS ONE, 2009 , 4 (e4236).

1261

333

1263

4811

Jones KA et al. Automated Patch Clamping Using the QPatch.
Methods Mol. Biol., 2009 , 565 (209-23).

1264

120159

1265

9073

Diochot S et al. Sea anemone toxins affecting potassium channels.
Prog. Mol. Subcell. Biol., 2009 , 46 (99-122).

1266

5067

1267

7622

Grunnet M et al. hERG1 channel activators: a new anti-arrhythmic principle.
Prog. Biophys. Mol. Biol., 2008 Oct-Nov , 98 (347-62).

1268

9014

Perrin MJ et al. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.
Prog. Biophys. Mol. Biol., 2008 Oct-Nov , 98 (137-48).

1269

3212

Mittelstadt SW et al. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG.
, 2008 Mar-Apr , 57 (100-5).

1270

8108

Filz O et al. Computer-aided prediction of QT-prolongation.
, 2008 Jan-Mar , 19 (81-90).

1272

10213

Fink M et al. Contributions of HERG K+ current to repolarization of the human ventricular action potential.
Prog. Biophys. Mol. Biol., 2008 Jan-Apr , 96 (357-76).

1275

3543

Gentile S et al. The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.
Proc. Natl. Acad. Sci. U.S.A., 2008 Sep 23 , 105 (14704-8).

1276

189

Abdel-Mottaleb Y et al. A common "hot spot" confers hERG blockade activity to alpha-scorpion toxins affecting K+ channels.
Biochem. Pharmacol., 2008 Sep 15 , 76 (805-15).

1277

913

Jo SH et al. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652.
Eur. J. Pharmacol., 2008 Sep 11 , 592 (19-25).

1279

2500

1280

4329

Ridley JM et al. Modulation by testosterone of an endogenous hERG potassium channel current.
J. Physiol. Pharmacol., 2008 Sep , 59 (395-407).

1282

5676

1284

4449

1286

132002

1287

606

Irie O et al. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.
Bioorg. Med. Chem. Lett., 2008 Oct 1 , 18 (5280-4).

1288

1812

1290

3492

1291

3284

Lin J et al. The regulation of the cardiac potassium channel (HERG) by caveolin-1.
Biochem. Cell Biol., 2008 Oct , 86 (405-15).

1292

8015

1293

7591

Yontar OC et al. Short QT syndrome: a very rare arrhythmogenic entity.
Acta Cardiol, 2008 Oct , 63 (553-5).

1295

6105

Wang X et al. [Analysis and analyzing mechanisms of HERG channel kinetics]
, 2008 Oct , 25 (1068-73).

1296

6734

Ravens U et al. Role of potassium currents in cardiac arrhythmias.
, 2008 Oct , 10 (1133-7).

1301

2023

Waldhauser KM et al. Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.
Br. J. Pharmacol., 2008 Oct , 155 (585-95).

1302

8821

Otagiri T et al. Cardiac ion channel gene mutations in sudden infant death syndrome.
Pediatr. Res., 2008 Nov , 64 (482-7).

1303

5926

1304

4194

Bowlby MR et al. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
Curr. Drug Metab., 2008 Nov , 9 (965-70).

1305

9732

Kamiya K et al. Molecular determinants of hERG channel block by terfenadine and cisapride.
J. Pharmacol. Sci., 2008 Nov , 108 (301-7).

1307

5343

Tenenbaum M et al. Identification of the gene causing long QT syndrome in an Israeli family.
Isr. Med. Assoc. J., 2008 Nov , 10 (809-11).

1308

9118

Wynia-Smith SL et al. hERG gating microdomains defined by S6 mutagenesis and molecular modeling.
J. Gen. Physiol., 2008 Nov , 132 (507-20).

1311

131907

1315

3123

Schimpf R et al. Clinical and molecular genetics of the short QT syndrome.
Curr. Opin. Cardiol., 2008 May , 23 (192-8).

1320

6942

Mitcheson JS hERG potassium channels and the structural basis of drug-induced arrhythmias.
Chem. Res. Toxicol., 2008 May , 21 (1005-10).

1321

6476

1322

132341

Andrássy G et al. Methadone-induced QTc prolongation: is it due to stereoselective block of hERG or to inappropriate QT interval correction?
Clin. Pharmacol. Ther., 2008 May , 83 (671; author reply 672).

1323

132146

Johnson JN et al. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.
Heart Rhythm, 2008 May , 5 (704-9).

1324

3183

Priest BT et al. Role of hERG potassium channel assays in drug development.
, 2008 Mar 5 , 2 ().

1328

9246

Zebedin E et al. Effects of duramycin on cardiac voltage-gated ion channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2008 Mar , 377 (87-100).

1329

7945

1331

7001

Raschi E et al. The hERG K+ channel: target and antitarget strategies in drug development.
Pharmacol. Res., 2008 Mar , 57 (181-95).

1332

3334

Mewe M et al. Erg K+ channels modulate contractile activity in the bovine epididymal duct.
Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008 Mar , 294 (R895-904).

1333

1050

Luo X et al. Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes.
Am. J. Physiol. Heart Circ. Physiol., 2008 Mar , 294 (H1371-80).

1334

8289

Gong Q et al. A splice site mutation in hERG leads to cryptic splicing in human long QT syndrome.
J. Mol. Cell. Cardiol., 2008 Mar , 44 (502-9).

1335

6829

Rhodes TE et al. Cardiac potassium channel dysfunction in sudden infant death syndrome.
J. Mol. Cell. Cardiol., 2008 Mar , 44 (571-81).

1338

3719

1340

6997

Zhang S et al. C101, a novel 4-amino-piperidine derivative selectively blocks N-type calcium channels.
Eur. J. Pharmacol., 2008 Jun 10 , 587 (42-7).

1341

9765

Jia L et al. Support vector machines classification of hERG liabilities based on atom types.
Bioorg. Med. Chem., 2008 Jun 1 , 16 (6252-60).

1343

49

Margulis M et al. Additive effects of combined application of multiple hERG blockers.
J. Cardiovasc. Pharmacol., 2008 Jun , 51 (549-52).

1345

9109

Rajamani S et al. Rapid kinetic interactions of ranolazine with HERG K+ current.
J. Cardiovasc. Pharmacol., 2008 Jun , 51 (581-9).

1346

2664

1350

149869

Crotti L et al. Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet., 2008 Jun , 123 (543).

1351

149883

Crotti L et al. Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet., 2008 Jun , 123 (541).

1352

149891

Crotti L et al. Gene symbol: KCNH2. Disease: Long QT syndrome.
Hum. Genet., 2008 Jun , 123 (540).

1353

1084

Tsai CT et al. Molecular genetics of atrial fibrillation.
J. Am. Coll. Cardiol., 2008 Jul 22 , 52 (241-50).

1355

5261

1358

1783

Hansen RS et al. In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
J. Cardiovasc. Pharmacol., 2008 Jul , 52 (35-41).

1359

3141

Scherer D et al. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.
Naunyn Schmiedebergs Arch. Pharmacol., 2008 Jul , 378 (73-83).

1360

9327

Kim KS et al. Electrophysiological safety of sibutramine HCl.
, 2008 Jul , 27 (553-8).

1361

120849

Shimizu W Genetics of congenital long QT syndrome and Brugada syndrome.
Future Cardiol, 2008 Jul , 4 (379-89).

1362

2704

1363

2027

Jo SH et al. Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
Life Sci., 2008 Jan 30 , 82 (331-40).

1364

12182

Thomas D et al. Doxazosin induces apoptosis of cells expressing hERG K+ channels.
Eur. J. Pharmacol., 2008 Jan 28 , 579 (98-103).

1365

10164

Zhao J et al. Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo.
Eur. J. Pharmacol., 2008 Jan 28 , 579 (50-7).

1367

15201

Albert CM et al. Cardiac sodium channel gene variants and sudden cardiac death in women.
Circulation, 2008 Jan 1 , 117 (16-23).

1369

16011

Shao XD et al. Expression and significance of HERG protein in gastric cancer.
Cancer Biol. Ther., 2008 Jan , 7 (45-50).

1370

122666

Qi ZP et al. [Effect of sophocarpine on HERG K+ channels]
Yao Xue Xue Bao, 2008 Jan , 43 (44-9).

1371

5048

Aronov AM Tuning out of hERG.
, 2008 Jan , 11 (128-40).

1374

132256

Jeyaraj D et al. I(Kr) channel blockade to unmask occult congenital long QT syndrome.
Heart Rhythm, 2008 Jan , 5 (2-7).

1375

5958

Gleeson MP Generation of a set of simple, interpretable ADMET rules of thumb.
J. Med. Chem., 2008 Feb 28 , 51 (817-34).

1377

11106

Wu L et al. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone.
Cardiovasc. Res., 2008 Feb 1 , 77 (481-8).

1378

18590

1379

16742

Kramer C et al. A composite model for HERG blockade.
, 2008 Feb , 3 (254-65).

1380

7563

Christ T et al. Electrophysiological profile of propiverine--relationship to cardiac risk.
Naunyn Schmiedebergs Arch. Pharmacol., 2008 Feb , 376 (431-40).

1381

15255

Garg D et al. Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques.
J. Mol. Graph. Model., 2008 Feb , 26 (966-76).

1382

132331

van der Heyden MA et al. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?
Br. J. Pharmacol., 2008 Feb , 153 (406-9).

1383

132378

1385

4662

Jones CD et al. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Bioorg. Med. Chem. Lett., 2008 Dec 15 , 18 (6486-9).

1386

9525

Jones CD et al. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Bioorg. Med. Chem. Lett., 2008 Dec 15 , 18 (6369-73).

1388

3720

Methot JL et al. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Bioorg. Med. Chem. Lett., 2008 Dec 1 , 18 (6104-9).

1390

966

1391

8527

1392

8345

Deisemann H et al. Effects of common antitussive drugs on the hERG potassium channel current.
J. Cardiovasc. Pharmacol., 2008 Dec , 52 (494-9).

1393

7496

Kim YJ et al. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
J. Cardiovasc. Pharmacol., 2008 Dec , 52 (485-93).

1398

9311

Zienciuk A et al. [QTc duration in the long QT syndrome type 2 - diagnostic dilemma]
, 2008 Dec , 66 (1333-7).

1399

2612

1400

4996

Nanduri J et al. Mitochondrial reactive oxygen species mediate hypoxic down-regulation of hERG channel protein.
Biochem. Biophys. Res. Commun., 2008 Aug 22 , 373 (309-14).

1401

9164

Sun DD et al. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels.
Eur. J. Pharmacol., 2008 Aug 20 , 590 (317-21).

1403

5661

Hancox JC et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Pharmacol. Ther., 2008 Aug , 119 (118-32).

1404

2235

1409

3628

1413

148635

Wang XP et al. [The persistent expression of HERG channel in Xenopus oocyte and alteration of current].
Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2008 Aug , 24 (329-33).

1415

2871

Thai KM et al. A binary QSAR model for classification of hERG potassium channel blockers.
Bioorg. Med. Chem., 2008 Apr 1 , 16 (4107-19).

1418

6117

Zhao XL et al. HERG K+ channel blockade by the novel antiviral drug sophocarpine.
Biol. Pharm. Bull., 2008 Apr , 31 (627-32).

1419

6840

1424

132202

Grunnet M Fetal arrhythmia caused by dysregulation of HERG channels.
Heart Rhythm, 2008 Apr , 5 (562-4).

1426

132209

Luo T et al. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Anesth. Analg., 2008 Apr , 106 (1161-70, table of contents).

1427

132200

Duff HJ hERG: the long and short of it.
Heart Rhythm, 2008 Apr , 5 (591-2).

1430

2934

1431

9927

Lundby A et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation.
Cell. Physiol. Biochem., 2008 , 21 (47-54).

1432

7803

Crotti L et al. Congenital long QT syndrome.
, 2008 , 3 (18).

1440

3451

1444

4538

1446

458

Aronov AM Ligand structural aspects of hERG channel blockade.
, 2008 , 8 (1113-27).

1447

7908

1448

6489

1449

3262

1450

2560

1451

105

1453

19503

Obrezanova O et al. Gaussian processes: a method for automatic QSAR modeling of ADME properties.
, 2007 Sep-Oct , 47 (1847-57).

1455

11138

Latorre R et al. ThermoTRP channels as modular proteins with allosteric gating.
Cell Calcium, 2007 Oct-Nov , 42 (427-38).

1457

14062

Donahue JK et al. Gene therapy approaches to ventricular tachyarrhythmias.
, 2007 Nov-Dec , 40 (S187-91).

1458

17041

Abbott GW et al. Impact of ancillary subunits on ventricular repolarization.
, 2007 Nov-Dec , 40 (S42-6).

1459

11401

Meyers NL et al. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
J. Int. Med. Res., 2007 Nov-Dec , 35 (848-66).

1461

2245

1466

11749

1468

11576

1469

11808

Johnson SR et al. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.
Bioorg. Med. Chem., 2007 Sep 15 , 15 (6182-92).

1470

15215

1471

19865

Su Z et al. Functional consequences of methionine oxidation of hERG potassium channels.
Biochem. Pharmacol., 2007 Sep 1 , 74 (702-11).

1473

16537

1474

11131

1477

13140

1478

16991

Nakamura K et al. Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome.
J. Am. Coll. Cardiol., 2007 Oct 30 , 50 (1808-9).

1481

10740

Cavarra MS et al. HERG1 currents in native K562 leukemic cells.
J. Membr. Biol., 2007 Oct , 219 (49-61).

1482

11655

Chung SK et al. Long QT and Brugada syndrome gene mutations in New Zealand.
, 2007 Oct , 4 (1306-14).

1483

16350

Bian JS et al. Phosphatidylinositol 4,5-bisphosphate interactions with the HERG K(+) channel.
Pflugers Arch., 2007 Oct , 455 (105-13).

1485

140

Li CL et al. [The mechanistic rote of KCNH2 gene L413P and L559H mutations in long QT syndrome]
Zhonghua Nei Ke Za Zhi, 2007 Oct , 46 (838-41).

1486

11981

Hardman RM et al. Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges.
J. Biol. Chem., 2007 Nov 2 , 282 (31972-81).

1487

10048

Bai X et al. Electrophysiological properties of human adipose tissue-derived stem cells.
Am. J. Physiol., Cell Physiol., 2007 Nov , 293 (C1539-50).

1488

17490

1489

17540

Dennis A et al. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Biochem. Soc. Trans., 2007 Nov , 35 (1060-3).

1491

15249

1493

17651

Gross MF et al. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Bioorg. Med. Chem. Lett., 2007 May 15 , 17 (2849-53).

1496

16873

Mikhail A et al. Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
J. Cardiovasc. Pharmacol., 2007 May , 49 (269-74).

1497

11591

Elmedyb P et al. Modulation of ERG channels by XE991.
Basic Clin. Pharmacol. Toxicol., 2007 May , 100 (316-22).

1499

17868

Wolpert C et al. [Short QT syndrome]
, 2007 May , 32 (206-10).

1501

132721

1503

13475

1504

10220

Waring MJ et al. A quantitative assessment of hERG liability as a function of lipophilicity.
Bioorg. Med. Chem. Lett., 2007 Mar 15 , 17 (1759-64).

1505

13755

1506

16876

Witchel HJ The hERG potassium channel as a therapeutic target.
Expert Opin. Ther. Targets, 2007 Mar , 11 (321-36).

1507

16511

Siebrands CC et al. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Anesthesiology, 2007 Mar , 106 (523-31).

1509

13886

Ly JQ et al. Assessing hERG channel inhibition using PatchXpress.
Clin. Lab. Med., 2007 Mar , 27 (201-8).

1511

10691

Hill AP et al. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1.
Biophys. J., 2007 Jun 1 , 92 (3915-29).

1513

16878

Li H et al. Expression and functional role of HERG1, K+ channels in leukemic cells and leukemic stem cells.
J. Huazhong Univ. Sci. Technol. Med. Sci., 2007 Jun , 27 (257-60).

1514

14269

Koo SH et al. Mutation screening in KCNQ1, HERG, KCNE1, KCNE2 and SCN5A genes in a long QT syndrome family.
Ann. Acad. Med. Singap., 2007 Jun , 36 (394-8).

1515

12965

1517

16805

Kiehne N et al. Mutations in the SCN5A gene: evidence for a link between long QT syndrome and sudden death?
Forensic Sci Int Genet, 2007 Jun , 1 (170-4).

1519

14428

Arnaout R et al. Zebrafish model for human long QT syndrome.
Proc. Natl. Acad. Sci. U.S.A., 2007 Jul 3 , 104 (11316-21).

1520

19389

Yabuuchi F et al. Reduction of hERG potassium currents by hyperosmolar solutions.
Eur. J. Pharmacol., 2007 Jul 2 , 566 (222-5).

1521

13714

Guan FY et al. [HERG K+ channel, the target of anti-arrhythmias drugs]
Yao Xue Xue Bao, 2007 Jul , 42 (687-91).

1522

12411

Beery TA et al. Neonatal long QT syndrome due to a de novo dominant negative hERG mutation.
Am. J. Crit. Care, 2007 Jul , 16 (416, 412-5).

1523

12472

1524

11491

Ocorr K et al. Genetic control of heart function and aging in Drosophila.
Trends Cardiovasc. Med., 2007 Jul , 17 (177-82).

1525

12418

Diller DJ et al. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
J. Comput. Aided Mol. Des., 2007 Jul , 21 (379-93).

1526

12848

1527

17328

1528

17877

Monassier L et al. sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart.
J. Pharmacol. Exp. Ther., 2007 Jul , 322 (341-50).

1530

17874

Sauer AJ et al. Long QT syndrome in adults.
J. Am. Coll. Cardiol., 2007 Jan 23 , 49 (329-37).

1531

132779

Arnestad M et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome.
Circulation, 2007 Jan 23 , 115 (361-7).

1532

132774

Tester DJ et al. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young.
J. Am. Coll. Cardiol., 2007 Jan 16 , 49 (240-6).

1537

11385

Nakajima T et al. HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function.
J. Biol. Chem., 2007 Feb 23 , 282 (5506-13).

1539

16308

1541

10802

Lengyel C et al. Diabetes mellitus attenuates the repolarization reserve in mammalian heart.
Cardiovasc. Res., 2007 Feb 1 , 73 (512-20).

1542

13619

1543

17653

Meyers KM et al. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
Bioorg. Med. Chem. Lett., 2007 Feb 1 , 17 (819-22).

1546

13821

Wang L et al. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
J. Pharmacol. Exp. Ther., 2007 Feb , 320 (525-34).

1548

13903

Siebrands CC et al. Inhibition of HERG channels by the local anaesthetic articaine.
, 2007 Feb , 24 (148-53).

1550

16411

1552

15035

Zhang Y et al. [Effects of matrine, oxymatrine and resveratrol on HERG channel expression]
Yao Xue Xue Bao, 2007 Feb , 42 (139-44).

1554

15573

Crotti L et al. Gene symbol: KCNH2.
Hum. Genet., 2007 Feb , 120 (911).

1555

14186

Crotti L et al. Gene symbol: KCNH2.
Hum. Genet., 2007 Feb , 120 (912).

1557

132324

Lu HR et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Eur. J. Pharmacol., 2007 Dec 22 , 577 (222-32).

1558

13245

Kelemen K et al. Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels.
Biochem. Biophys. Res. Commun., 2007 Dec 21 , 364 (429-35).

1560

13633

1561

7798

Gongadze N et al. Prolong QT interval and "torsades de pointes" associated with different group of drugs.
Georgian Med News, 2007 Dec , (45-9).

1562

12183

Perry M et al. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
Proc. Natl. Acad. Sci. U.S.A., 2007 Aug 21 , 104 (13827-32).

1564

18299

Walker VE et al. Co-chaperone FKBP38 promotes HERG trafficking.
J. Biol. Chem., 2007 Aug 10 , 282 (23509-16).

1565

19683

Stansfeld PJ et al. Drug block of the hERG potassium channel: insight from modeling.
Proteins, 2007 Aug 1 , 68 (568-80).

1566

12014

Duncan RS et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
Biochem. Pharmacol., 2007 Aug 1 , 74 (425-37).

1567

18055

Stork D et al. State dependent dissociation of HERG channel inhibitors.
Br. J. Pharmacol., 2007 Aug , 151 (1368-76).

1570

11608

Elmedyb P et al. Activation of ERG2 potassium channels by the diphenylurea NS1643.
Neuropharmacology, 2007 Aug , 53 (283-94).

1571

13660

Danielsson C et al. Polytherapy with hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia and teratogenicity.
Birth Defects Res. Part A Clin. Mol. Teratol., 2007 Aug , 79 (595-603).

1573

19452

1574

12536

Du L et al. A novel structure-based virtual screening model for the hERG channel blockers.
Biochem. Biophys. Res. Commun., 2007 Apr 20 , 355 (889-94).

1575

16370

Judd AS et al. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Bioorg. Med. Chem. Lett., 2007 Apr 15 , 17 (2365-71).

1576

12279

Jo SH et al. Maprotiline block of the human ether-a-go-go-related gene (HERG) K+ channel.
Arch. Pharm. Res., 2007 Apr , 30 (453-60).

1577

14285

Gavaghan CL et al. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data.
J. Comput. Aided Mol. Des., 2007 Apr , 21 (189-206).

1578

19744

1580

16844

Um SY et al. Differential association between HERG and KCNE1 or KCNE2.
PLoS ONE, 2007 , 2 (e933).

1583

15048

1585

9805

1587

27068

1588

22109

1590

23877

1591

16923

1597

28595

Song M et al. Development and evaluation of an in silico model for hERG binding.
, 2006 Jan-Feb , 46 (392-400).

1600

28910

Price DA et al. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
Bioorg. Med. Chem. Lett., 2006 Sep 1 , 16 (4633-7).

1604

133005

1605

12190

1606

18602

Heradien MJ et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation?
J. Am. Coll. Cardiol., 2006 Oct 3 , 48 (1410-5).

1608

15408

Choe CU et al. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.
Hum. Mol. Genet., 2006 Oct 1 , 15 (2888-902).

1610

13079

1613

16358

Zareba W Genotype-specific ECG patterns in long QT syndrome.
, 2006 Oct , 39 (S101-6).

1614

19537

1615

13823

Lu LX et al. Short QT syndrome: a case report and review of literature.
, 2006 Oct , 71 (115-21).

1618

16364

1619

16198

Wu S et al. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
Bioorg. Med. Chem. Lett., 2006 Nov 15 , 16 (5859-63).

1620

17955

Fluxe A et al. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers.
Bioorg. Med. Chem. Lett., 2006 Nov 15 , 16 (5855-8).

1621

132855

1622

18097

Zhu BY et al. Inhibitory effect of carboxylic acid group on hERG binding.
Bioorg. Med. Chem. Lett., 2006 Nov 1 , 16 (5507-12).

1623

16943

Zeng H et al. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
J. Pharmacol. Exp. Ther., 2006 Nov , 319 (957-62).

1625

14468

1627

19747

Sasano T et al. Molecular ablation of ventricular tachycardia after myocardial infarction.
Nat. Med., 2006 Nov , 12 (1256-8).

1631

23028

Choe H et al. A novel hypothesis for the binding mode of HERG channel blockers.
Biochem. Biophys. Res. Commun., 2006 May 26 , 344 (72-8).

1632

25053

Diness TG et al. Frequency-dependent modulation of KCNQ1 and HERG1 potassium channels.
Biochem. Biophys. Res. Commun., 2006 May 19 , 343 (1224-33).

1633

29161

1634

29331

Coi A et al. Prediction of hERG potassium channel affinity by the CODESSA approach.
Bioorg. Med. Chem., 2006 May 1 , 14 (3153-9).

1635

27993

1636

21997

Guo J et al. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
J. Pharmacol. Exp. Ther., 2006 May , 317 (865-74).

1637

24374

Kamiya K et al. Molecular determinants of HERG channel block.
Mol. Pharmacol., 2006 May , 69 (1709-16).

1639

20779

Fedida D et al. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
J. Cardiovasc. Electrophysiol., 2006 May , 17 Suppl 1 (S71-S78).

1641

29535

Storey NM et al. Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone.
Proc. Natl. Acad. Sci. U.S.A., 2006 Mar 28 , 103 (5197-201).

1642

29777

Gentile S et al. Rac GTPase signaling through the PP5 protein phosphatase.
Proc. Natl. Acad. Sci. U.S.A., 2006 Mar 28 , 103 (5202-6).

1643

27013

Sanguinetti MC et al. hERG potassium channels and cardiac arrhythmia.
Nature, 2006 Mar 23 , 440 (463-9).

1645

22234

Raab CE et al. Synthesis of the first sulfur-35-labeled hERG radioligand.
Bioorg. Med. Chem. Lett., 2006 Mar 15 , 16 (1692-5).

1646

21586

Duncan RS et al. Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652.
Biochem. Biophys. Res. Commun., 2006 Mar 10 , 341 (500-6).

1648

23421

1651

29291

Modell SM et al. The long QT syndrome family of cardiac ion channelopathies: a HuGE review.
Genet. Med., 2006 Mar , 8 (143-55).

1653

27826

Zhang S Isolation and characterization of I(Kr) in cardiac myocytes by Cs+ permeation.
Am. J. Physiol. Heart Circ. Physiol., 2006 Mar , 290 (H1038-49).

1654

23906

Rajamani S et al. Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr).
Am. J. Physiol. Heart Circ. Physiol., 2006 Mar , 290 (H1278-88).

1656

133238

Sarzani R et al. The functional HERG variant 897T is associated with Conn's adenoma.
J. Hypertens., 2006 Mar , 24 (479-87).

1657

133169

Clarke CE et al. Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.
J. Physiol. (Lond.), 2006 Jun 1 , 573 (291-304).

1659

23245

Kiesecker C et al. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2006 Jun , 373 (212-20).

1663

10026

1664

24938

1665

23481

Ro S et al. Template switching within exons 3 and 4 of KV11.1 (HERG) gives rise to a 5' truncated cDNA.
Biochem. Biophys. Res. Commun., 2006 Jul 14 , 345 (1342-9).

1667

29310

Gang H et al. Na+ permeation and block of hERG potassium channels.
J. Gen. Physiol., 2006 Jul , 128 (55-71).

1668

26269

Patel ND et al. The heterogeneous spectrum of the long QT syndrome.
Eur. J. Intern. Med., 2006 Jul , 17 (235-40).

1670

26969

Vandenberg JI et al. Temperature dependence of human ether-a-go-go-related gene K+ currents.
Am. J. Physiol., Cell Physiol., 2006 Jul , 291 (C165-75).

1674

28402

1675

29090

1676

22756

Su Z et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Biochem. Pharmacol., 2006 Jan 12 , 71 (278-86).

1678

24229

1679

26696

Rudy Y Modelling and imaging cardiac repolarization abnormalities.
J. Intern. Med., 2006 Jan , 259 (91-106).

1680

26719

Ridley JM et al. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
J. Mol. Cell. Cardiol., 2006 Jan , 40 (107-18).

1681

22803

Furuzono S et al. Inherent pacemaker function of duodenal GIST.
Eur. J. Cancer, 2006 Jan , 42 (243-8).

1688

29732

Möller C et al. Effects of estradiol on cardiac ion channel currents.
Eur. J. Pharmacol., 2006 Feb 17 , 532 (44-9).

1689

28863

Ferrer-Villada T et al. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline.
Eur. J. Pharmacol., 2006 Feb 15 , 531 (1-8).

1690

21986

Kirchberger NM et al. Effects of TRH on heteromeric rat erg1a/1b K+ channels are dominated by the rerg1b subunit.
J. Physiol. (Lond.), 2006 Feb 15 , 571 (27-42).

1695

24551

Trepakova ES et al. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
J. Cardiovasc. Pharmacol., 2006 Feb , 47 (211-20).

1697

25119

Casis O et al. Mechanism of action of a novel human ether-a-go-go-related gene channel activator.
Mol. Pharmacol., 2006 Feb , 69 (658-65).

1698

27421

1700

28272

Rudy Y et al. Computational biology in the study of cardiac ion channels and cell electrophysiology.
Q. Rev. Biophys., 2006 Feb , 39 (57-116).

1701

122431

Stansfeld PJ et al. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Expert Opin Drug Metab Toxicol, 2006 Feb , 2 (81-94).

1702

26326

Cockerill SL et al. Direct block of human ether-a-go-go-related gene potassium channels by caffeine.
J. Pharmacol. Exp. Ther., 2006 Feb , 316 (860-8).

1704

16836

Milnes JT et al. hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656.
Biochem. Biophys. Res. Commun., 2006 Dec 8 , 351 (273-80).

1705

13086

1706

132887

Lu HR et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Eur. J. Pharmacol., 2006 Dec 28 , 553 (229-39).

1708

10830

Saenen JB et al. Modulation of HERG gating by a charge cluster in the N-terminal proximal domain.
Biophys. J., 2006 Dec 15 , 91 (4381-91).

1711

19196

Waldhauser KM et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.
J. Pharmacol. Exp. Ther., 2006 Dec , 319 (1413-23).

1713

18301

1714

19571

Lamarca V et al. K+ channels involved in contractility of rabbit small intestine.
J. Physiol. Biochem., 2006 Dec , 62 (227-36).

1715

132816

1716

13284

Jamieson C et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
J. Med. Chem., 2006 Aug 24 , 49 (5029-46).

1718

12423

Kim MD et al. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
Eur. J. Pharmacol., 2006 Aug 21 , 544 (82-90).

1720

21564

Roepke TK et al. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion.
J. Biol. Chem., 2006 Aug 18 , 281 (23740-7).

1723

28057

Gepp MM et al. Determination of hERG channel blockers using a decision tree.
Bioorg. Med. Chem., 2006 Aug 1 , 14 (5325-32).

1727

25181

Huscroft IT et al. 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
Bioorg. Med. Chem. Lett., 2006 Apr 1 , 16 (2008-12).

1733

29632

Alexandrou AJ et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Br. J. Pharmacol., 2006 Apr , 147 (905-16).

1735

27929

Lawson K et al. Modulation of potassium channels as a therapeutic approach.
Curr. Pharm. Des., 2006 , 12 (459-70).

1736

23512

Robertson GA et al. HERG trafficking and pharmacological rescue of LQTS-2 mutant channels.
Handb Exp Pharmacol, 2006 , (349-55).

1738

23717

1742

15580

Maier G et al. Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3.
Cell. Physiol. Biochem., 2006 , 18 (177-86).

1746

165455

1752

24100

1753

28500

1754

20560

Anson BD et al. Blockade of HERG channels by HIV protease inhibitors.
Lancet, 2005 Feb 19-25 , 365 (682-6).

1755

20586

Shim SH et al. Gene sequencing in neonates and infants with the long QT syndrome.
Genet. Test., 2005 Winter , 9 (281-4).

1758

29065

Yao X et al. Propranolol inhibits the human ether-a-go-go-related gene potassium channels.
Eur. J. Pharmacol., 2005 Sep 20 , 519 (208-11).

1759

23647

1762

20682

1764

27413

Berge KE et al. [DNA-based diagnostics of long QT syndrome]
Tidsskr. Nor. Laegeforen., 2005 Oct 20 , 125 (2783-6).

1768

22891

Jiang M et al. Dynamic conformational changes of extracellular S5-P linkers in the hERG channel.
J. Physiol. (Lond.), 2005 Nov 15 , 569 (75-89).

1769

28570

1771

29009

Guizy M et al. {Omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels.
Am. J. Physiol., Cell Physiol., 2005 Nov , 289 (C1251-60).

1774

20689

1775

26102

1777

24393

Höfner G et al. NMDA-NR2B subtype selectivity of stereoisomeric 2-(1,2,3,4-tetrahydro-1-isoquinolyl)ethanol derivatives.
Bioorg. Med. Chem. Lett., 2005 May 2 , 15 (2231-4).

1780

22877

1781

26835

Haugan K et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress.
J. Cardiovasc. Electrophysiol., 2005 May , 16 (537-45).

1783

133623

Cordes JS et al. Pentamidine reduces hERG expression to prolong the QT interval.
Br. J. Pharmacol., 2005 May , 145 (15-23).

1784

133624

Eckhardt LL et al. Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
Br. J. Pharmacol., 2005 May , 145 (3-4).

1785

23704

Tarantino P et al. Effect of trazodone on hERG channel current and QT-interval.
Eur. J. Pharmacol., 2005 Mar 7 , 510 (75-85).

1787

23684

Rajamani R et al. A two-state homology model of the hERG K+ channel: application to ligand binding.
Bioorg. Med. Chem. Lett., 2005 Mar 15 , 15 (1737-41).

1788

28204

Hofer AM Another dimension to calcium signaling: a look at extracellular calcium.
J. Cell. Sci., 2005 Mar 1 , 118 (855-62).

1789

30774

1790

27039

Danielsson BR et al. Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism.
Birth Defects Res. Part A Clin. Mol. Teratol., 2005 Mar , 73 (146-53).

1792

20481

Kikuchi K et al. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Br. J. Pharmacol., 2005 Mar , 144 (840-8).

1793

26593

Lin C et al. The influence of extracellular acidosis on the effect of IKr blockers.
J. Cardiovasc. Pharmacol. Ther., 2005 Mar , 10 (67-76).

1794

26899

Pandini A et al. Conservation and specialization in PAS domain dynamics.
Protein Eng. Des. Sel., 2005 Mar , 18 (127-37).

1795

28909

1796

24259

Sanguinetti MC et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Trends Pharmacol. Sci., 2005 Mar , 26 (119-24).

1800

133671

De Bruin ML et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
Eur. Heart J., 2005 Mar , 26 (590-7).

1801

133684

Seebohm G Activators of cation channels: potential in treatment of channelopathies.
Mol. Pharmacol., 2005 Mar , 67 (585-8).

1803

23183

1804

28951

Du R et al. [Relationship between congenital long QT syndrome and Brugada syndrome gene mutation]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005 Jun , 27 (289-94).

1809

21981

Pihl J et al. Microfluidic gradient-generating device for pharmacological profiling.
Anal. Chem., 2005 Jul 1 , 77 (3897-903).

1811

25074

1814

23414

1815

27407

Wolpert C et al. Clinical characteristics and treatment of short QT syndrome.
, 2005 Jul , 3 (611-7).

1816

27023

1817

133494

Shah RR et al. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
Heart Rhythm, 2005 Jul , 2 (758-72).

1818

36381

1819

21162

Aronov AM Predictive in silico modeling for hERG channel blockers.
Drug Discov. Today, 2005 Jan 15 , 10 (149-55).

1820

30571

Royer A et al. Expression of human ERG K+ channels in the mouse heart exerts anti-arrhythmic activity.
Cardiovasc. Res., 2005 Jan 1 , 65 (128-37).

1821

31538

Kuryshev YA et al. Pentamidine-induced long QT syndrome and block of hERG trafficking.
J. Pharmacol. Exp. Ther., 2005 Jan , 312 (316-23).

1822

33120

Ramakers C et al. Molecular and electrical characterization of the canine cardiac ventricular septum.
J. Mol. Cell. Cardiol., 2005 Jan , 38 (153-61).

1823

37584

Wolpert C et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.
J. Cardiovasc. Electrophysiol., 2005 Jan , 16 (54-8).

1825

36581

Berecki G et al. HERG channel (dys)function revealed by dynamic action potential clamp technique.
Biophys. J., 2005 Jan , 88 (566-78).

1826

29388

1828

31389

1829

26864

O'Brien SE et al. Greater than the sum of its parts: combining models for useful ADMET prediction.
J. Med. Chem., 2005 Feb 24 , 48 (1287-91).

1832

133646

1834

35203

Aydin A et al. Single nucleotide polymorphism map of five long-QT genes.
J. Mol. Med., 2005 Feb , 83 (159-65).

1835

36915

Dupuis DS et al. Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels.
Basic Clin. Pharmacol. Toxicol., 2005 Feb , 96 (123-30).

1838

22558

1841

23908

1842

20940

Jalaie M et al. QT interval prolongation: and the beat goes on.
, 2005 Dec , 5 (1083-91).

1845

133429

Crotti L et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome.
Circulation, 2005 Aug 30 , 112 (1251-8).

1846

23923

1847

25546

1848

25049

Schimpf R et al. Short QT syndrome.
Cardiovasc. Res., 2005 Aug 15 , 67 (357-66).

1850

24899

Shimizu W The long QT syndrome: therapeutic implications of a genetic diagnosis.
Cardiovasc. Res., 2005 Aug 15 , 67 (347-56).

1853

22238

Cianchetta G et al. Predictive models for hERG potassium channel blockers.
Bioorg. Med. Chem. Lett., 2005 Aug 1 , 15 (3637-42).

1855

28169

Chen SZ et al. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Cancer Chemother. Pharmacol., 2005 Aug , 56 (212-20).

1856

24744

1860

133600

Priori SG et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.
Circ. Res., 2005 Apr 15 , 96 (800-7).

1861

32787

Sturm P et al. Extracellular potassium effects are conserved within the rat erg K+ channel family.
J. Physiol. (Lond.), 2005 Apr 15 , 564 (329-45).

1862

36743

Hirdes W et al. Fast erg K+ currents in rat embryonic serotonergic neurones.
J. Physiol. (Lond.), 2005 Apr 1 , 564 (33-49).

1864

29123

Dilaveris PE Molecular predictors of drug-induced prolongation of the QT interval.
Curr Med Chem Cardiovasc Hematol Agents, 2005 Apr , 3 (105-18).

1865

28825

Eun JS et al. Effects of oxypeucedanin on hKv1.5 and action potential duration.
Biol. Pharm. Bull., 2005 Apr , 28 (657-60).

1866

30379

Claassen S et al. Comparison of the effects of metoclopramide and domperidone on HERG channels.
Pharmacology, 2005 Apr , 74 (31-6).

1867

35957

1868

133572

Hong K et al. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2.
J. Cardiovasc. Electrophysiol., 2005 Apr , 16 (394-6).

1869

24778

Anantharam A et al. Does hERG coassemble with a beta subunit? Evidence for roles of MinK and MiRP1.
Novartis Found. Symp., 2005 , 266 (100-12; discussion 112-7, 155-8).

1870

22222

Robertson GA et al. Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart.
Novartis Found. Symp., 2005 , 266 (4-15; discussion 15-8, 44-5).

1871

22776

1872

29303

Tseng GN et al. Structure-function studies of the outer mouth and voltage sensor domain of hERG.
Novartis Found. Symp., 2005 , 266 (19-35; discussion 35-45).

1874

22112

Piper DR et al. Voltage sensor movement in the hERG K+ channel.
Novartis Found. Symp., 2005 , 266 (46-52; discussion 52-6, 95-9).

1875

29078

Ficker E et al. HERG channel trafficking.
Novartis Found. Symp., 2005 , 266 (57-69; discussion 70-4, 95-9).

1876

25907

Kagan A et al. Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3.
Novartis Found. Symp., 2005 , 266 (75-89; discussion 89-99).

1878

20307

Shah RR Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Novartis Found. Symp., 2005 , 266 (251-80; discussion 280-5).

1880

25339

Brown AM HERG block, QT liability and sudden cardiac death.
Novartis Found. Symp., 2005 , 266 (118-31; discussion 131-5, 155-8).

1881

22269

Mitcheson J et al. Structural determinants for high-affinity block of hERG potassium channels.
Novartis Found. Symp., 2005 , 266 (136-50; discussion 150-8).

1882

27018

Sanguinetti MC et al. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Novartis Found. Symp., 2005 , 266 (159-66; discussion 166-70).

1883

25987

Recanatini M et al. In silico modelling--pharmacophores and hERG channel models.
Novartis Found. Symp., 2005 , 266 (171-81; discussion 181-5).

1884

29629

Schwartz PJ The long QT syndrome: a clinical counterpart of hERG mutations.
Novartis Found. Symp., 2005 , 266 (186-98; discussion 198-203).

1885

28651

Arcangeli A Expression and role of hERG channels in cancer cells.
Novartis Found. Symp., 2005 , 266 (225-32; discussion 232-4).

1886

24558

Kim KS et al. The phenothiazine drugs inhibit hERG potassium channels.
, 2005 , 28 (303-13).

1888

22129

1889

35280

Chatrath R et al. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome.
Pediatr Cardiol, 2004 Sep-Oct , 25 (459-65).

1891

38302

1893

33897

Korolkova YV et al. Unique interaction of scorpion toxins with the hERG channel.
J. Mol. Recognit., 2004 May-Jun , 17 (209-17).

1894

31156

Patt S et al. Expression of ether à go-go potassium channels in human gliomas.
Neurosci. Lett., 2004 Sep 30 , 368 (249-53).

1895

34009

Zhang L et al. An intronic mutation causes long QT syndrome.
J. Am. Coll. Cardiol., 2004 Sep 15 , 44 (1283-91).

1897

31403

Kääb S et al. Long QT syndrome. Why does sex matter?
, 2004 Sep , 93 (641-5).

1898

36012

Gögelein H et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2004 Sep , 370 (183-92).

1899

133560

1900

33402

Jones EM et al. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits.
J. Biol. Chem., 2004 Oct 22 , 279 (44690-4).

1902

33198

1903

31724

Finlayson K et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Eur. J. Pharmacol., 2004 Oct 1 , 500 (129-42).

1906

33793

1908

133732

Opdal SH et al. The sudden infant death syndrome gene: does it exist?
Pediatrics, 2004 Oct , 114 (e506-12).

1909

37101

Zehelein J et al. Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome.
Biochim. Biophys. Acta, 2004 Nov 5 , 1690 (185-92).

1911

30318

Bilchick K et al. Temporal repolarization lability differences among genotyped patients with the long QT syndrome.
Am. J. Cardiol., 2004 Nov 15 , 94 (1312-6).

1912

37128

Davie C et al. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
J. Cardiovasc. Electrophysiol., 2004 Nov , 15 (1302-9).

1913

32487

1914

37995

1915

32115

1916

30556

Bellocq C et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2.
Mol. Pharmacol., 2004 Nov , 66 (1093-102).

1917

34364

Bian JS et al. Molecular analysis of PIP2 regulation of HERG and IKr.
Am. J. Physiol. Heart Circ. Physiol., 2004 Nov , 287 (H2154-63).

1918

33496

Arcangeli A et al. Physical and functional interaction between integrins and hERG potassium channels.
Biochem. Soc. Trans., 2004 Nov , 32 (826-7).

1919

30462

Sun Z et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
J. Mol. Cell. Cardiol., 2004 Nov , 37 (1031-9).

1920

39585

Chugh SS et al. Postmortem molecular screening in unexplained sudden death.
J. Am. Coll. Cardiol., 2004 May 5 , 43 (1625-9).

1921

37914

1922

37904

Bellocq C et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome.
Circulation, 2004 May 25 , 109 (2394-7).

1923

39010

Clark RB et al. A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells.
Am. J. Physiol. Heart Circ. Physiol., 2004 May , 286 (H1757-66).

1924

39066

Lee SY et al. Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.
J. Cardiovasc. Pharmacol., 2004 May , 43 (706-14).

1925

34646

1926

30891

1927

30524

Dong DL et al. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Basic Clin. Pharmacol. Toxicol., 2004 May , 94 (209-12).

1928

32075

1929

34766

Ridley JM et al. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
J. Mol. Cell. Cardiol., 2004 May , 36 (701-5).

1930

37412

1931

31613

1933

30013

Fernandez D et al. Physicochemical features of the HERG channel drug binding site.
J. Biol. Chem., 2004 Mar 12 , 279 (10120-7).

1935

32665

Kang J et al. Cardiac ion channel effects of tolterodine.
J. Pharmacol. Exp. Ther., 2004 Mar , 308 (935-40).

1936

33312

1938

133941

1940

36207

Tsujimae K et al. Comparison of kinetic properties of quinidine and dofetilide block of HERG channels.
Eur. J. Pharmacol., 2004 Jun 16 , 493 (29-40).

1941

31627

Wang S et al. Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence.
J. Physiol. (Lond.), 2004 Jun 15 , 557 (705-17).

1942

38926

Brown AM Drugs, hERG and sudden death.
Cell Calcium, 2004 Jun , 35 (543-7).

1943

36409

Hua F et al. Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes.
Am. J. Physiol. Heart Circ. Physiol., 2004 Jun , 286 (H2342-51).

1944

33582

1945

37227

Anson BD et al. Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels.
Am. J. Physiol. Heart Circ. Physiol., 2004 Jun , 286 (H2434-41).

1946

33433

Lian JF et al. [Long QT syndrome gene diagnosis by haplotype analysis]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2004 Jun , 21 (272-3).

1947

31133

Subbiah RN et al. Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel.
J. Physiol. (Lond.), 2004 Jul 15 , 558 (417-31).

1948

34239

1949

37887

Ficker E et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization.
Mol. Pharmacol., 2004 Jul , 66 (33-44).

1950

32608

Tsai HF et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension.
Antimicrob. Agents Chemother., 2004 Jul , 48 (2483-9).

1952

32573

1953

31561

Chiu PJ et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
J. Pharmacol. Sci., 2004 Jul , 95 (311-9).

1954

34841

Conti M Targeting K+ channels for cancer therapy.
J. Exp. Ther. Oncol., 2004 Jul , 4 (161-6).

1955

32367

Youm JB et al. Modulation of HERG channel inactivation by external cations.
Eur. Biophys. J., 2004 Jul , 33 (360-9).

1957

31814

1958

36934

Brugada R et al. Sudden death associated with short-QT syndrome linked to mutations in HERG.
Circulation, 2004 Jan 6 , 109 (30-5).

1960

38293

Traebert M et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.
Eur. J. Pharmacol., 2004 Jan 19 , 484 (41-8).

1963

33256

Varró A et al. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Curr. Med. Chem., 2004 Jan , 11 (1-11).

1964

30727

Su Z et al. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.
J. Mol. Cell. Cardiol., 2004 Jan , 36 (151-60).

1965

37692

Fossa AA et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Eur. J. Pharmacol., 2004 Feb 20 , 486 (209-21).

1967

39154

Kobori A et al. Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome.
J. Cardiovasc. Electrophysiol., 2004 Feb , 15 (190-9).

1968

32720

1972

34969

1973

32999

Subbiah RN et al. Inherited cardiac arrhythmia syndromes: what have they taught us about arrhythmias and anti-arrhythmic therapy?
Clin. Exp. Pharmacol. Physiol., 2004 Dec , 31 (906-12).

1974

38867

Sánchez-Chapula JA et al. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Naunyn Schmiedebergs Arch. Pharmacol., 2004 Dec , 370 (484-91).

1975

37796

Zhang M et al. Gating charges in the activation and inactivation processes of the HERG channel.
J. Gen. Physiol., 2004 Dec , 124 (703-18).

1976

33959

Kiesecker C et al. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.
Naunyn Schmiedebergs Arch. Pharmacol., 2004 Dec , 370 (423-35).

1979

31331

1980

32783

1981

35071

1982

33758

Hirdes W et al. Muscarinic modulation of erg potassium current.
J. Physiol. (Lond.), 2004 Aug 15 , 559 (67-84).

1985

34032

1987

30374

1988

32847

Schram G et al. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
Br. J. Pharmacol., 2004 Aug , 142 (1300-8).

1989

35144

Perry M et al. Structural determinants of HERG channel block by clofilium and ibutilide.
Mol. Pharmacol., 2004 Aug , 66 (240-9).

1990

36762

Zitron E et al. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
Naunyn Schmiedebergs Arch. Pharmacol., 2004 Aug , 370 (146-56).

1991

198300

1992

32694

Westenskow P et al. Compound mutations: a common cause of severe long-QT syndrome.
Circulation, 2004 Apr 20 , 109 (1834-41).

1995

37044

Tamargo J et al. Pharmacology of cardiac potassium channels.
Cardiovasc. Res., 2004 Apr 1 , 62 (9-33).

1996

33023

Rasmussen HB et al. Subcellular localization of the delayed rectifier K(+) channels KCNQ1 and ERG1 in the rat heart.
Am. J. Physiol. Heart Circ. Physiol., 2004 Apr , 286 (H1300-9).

1998

39044

2000

30025

2001

39231

Charpentier F et al. Cardiac channelopathies: from men to mice.
Ann. Med., 2004 , 36 Suppl 1 (28-34).

2002

35103

Thomas D et al. Modulation of HERG potassium channel function by drug action.
Ann. Med., 2004 , 36 Suppl 1 (41-6).

2003

32435

Bian JS et al. S641 contributes HERG K+ channel inactivation.
Cell Biochem. Biophys., 2004 , 41 (25-40).

2006

33774

Danielsson BR et al. Phenytoin and phenobarbital inhibit human HERG potassium channels.
Epilepsy Res., 2003 Jun-Jul , 55 (147-57).

2007

46880

Finley MR et al. Structural and functional basis for the long QT syndrome: relevance to veterinary patients.
J. Vet. Intern. Med., 2003 Jul-Aug , 17 (473-88).

2008

33934

Piper DR et al. Gating currents associated with intramembrane charge displacement in HERG potassium channels.
Proc. Natl. Acad. Sci. U.S.A., 2003 Sep 2 , 100 (10534-9).

2009

48989

Delisle BP et al. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C.
J. Biol. Chem., 2003 Sep 12 , 278 (35749-54).

2011

36754

2012

39702

Borlak J et al. Hallmarks of ion channel gene expression in end-stage heart failure.
FASEB J., 2003 Sep , 17 (1592-608).

2013

36735

Wu LM et al. Effects of Na+ channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells.
J. Cardiovasc. Pharmacol., 2003 Sep , 42 (410-8).

2014

37518

Mitcheson JS et al. Molecular determinants of high-affinity drug binding to HERG channels.
, 2003 Sep , 6 (667-74).

2015

134049

Witzenbichler B et al. [18-year old patient with anti-epileptic therapy and sudden cardiac death]
Z Kardiol, 2003 Sep , 92 (747-53).

2016

134073

2018

33097

Fedida D et al. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
Circ. Res., 2003 Oct 17 , 93 (744-51).

2019

30821

Laohakunakorn P et al. Bidirectional ventricular tachycardia and channelopathy.
Am. J. Cardiol., 2003 Oct 15 , 92 (991-5).

2021

40835

Angelo K et al. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.
Pflugers Arch., 2003 Oct , 447 (55-63).

2023

41653

Zicha S et al. Molecular basis of species-specific expression of repolarizing K+ currents in the heart.
Am. J. Physiol. Heart Circ. Physiol., 2003 Oct , 285 (H1641-9).

2024

35053

Zolotoy AB et al. Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding.
Curr Med Chem Cardiovasc Hematol Agents, 2003 Oct , 1 (225-41).

2025

33760

Brendel J et al. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
Curr Med Chem Cardiovasc Hematol Agents, 2003 Oct , 1 (273-87).

2026

37594

Lee K et al. IKr channel blockers: novel antiarrhythmic agents.
Curr Med Chem Cardiovasc Hematol Agents, 2003 Oct , 1 (203-23).

2028

133992

2033

133979

Zareba W et al. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.
J. Cardiovasc. Electrophysiol., 2003 Nov , 14 (1149-53).

2034

134159

Priori SG et al. Risk stratification in the long-QT syndrome.
N. Engl. J. Med., 2003 May 8 , 348 (1866-74).

2035

40247

Pearlstein RA et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Bioorg. Med. Chem. Lett., 2003 May 19 , 13 (1829-35).

2036

42649

Zhang S et al. Modulation of human ether-à-go-go-related K+ (HERG) channel inactivation by Cs+ and K+.
J. Physiol. (Lond.), 2003 May 1 , 548 (691-702).

2040

45324

Torres AM et al. Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin.
FEBS Lett., 2003 Mar 27 , 539 (138-42).

2042

46119

Milan DJ et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish.
Circulation, 2003 Mar 18 , 107 (1355-8).

2043

44024

2046

42981

Parr E et al. ERG K+ channels modulate the electrical and contractile activities of gallbladder smooth muscle.
Am. J. Physiol. Gastrointest. Liver Physiol., 2003 Mar , 284 (G392-8).

2047

44013

Arias C et al. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
Cardiovasc. Res., 2003 Mar , 57 (660-9).

2049

40490

2051

46394

Ridley JM et al. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Biochem. Biophys. Res. Commun., 2003 Jun 27 , 306 (388-93).

2052

45612

2053

42073

2054

40849

2056

48834

Farrelly AM et al. Expression and function of KCNH2 (HERG) in the human jejunum.
Am. J. Physiol. Gastrointest. Liver Physiol., 2003 Jun , 284 (G883-95).

2057

40265

Wang J et al. Saxitoxin is a gating modifier of HERG K+ channels.
J. Gen. Physiol., 2003 Jun , 121 (583-98).

2059

43072

Thomas D et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
Br. J. Pharmacol., 2003 Jun , 139 (567-74).

2060

41702

2062

43658

Amos GJ et al. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
J. Cardiovasc. Electrophysiol., 2003 Jun , 14 (651-8).

2063

49315

Zareba W et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.
J. Am. Coll. Cardiol., 2003 Jul 2 , 42 (103-9).

2066

46632

Bezzina CR et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization.
Cardiovasc. Res., 2003 Jul 1 , 59 (27-36).

2068

49291

Thomas D et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.
Naunyn Schmiedebergs Arch. Pharmacol., 2003 Jul , 368 (41-8).

2070

134121

2071

134120

2072

45404

Crociani O et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells.
J. Biol. Chem., 2003 Jan 31 , 278 (2947-55).

2075

47647

Mühlbauer E et al. Ethanol differently affects stress protein and HERG K+ channel expression in SH-SY5Y cells.
Eur. J. Pharmacol., 2003 Jan 17 , 459 (121-9).

2077

45211

Kang J et al. Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels.
Eur. J. Pharmacol., 2003 Jan 1 , 458 (25-9).

2078

44366

2079

48620

Tristani-Firouzi M et al. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating.
J. Mol. Cell. Cardiol., 2003 Jan , 35 (27-35).

2080

49583

Wang J et al. Functional and pharmacological properties of canine ERG potassium channels.
Am. J. Physiol. Heart Circ. Physiol., 2003 Jan , 284 (H256-67).

2082

45051

2083

46857

D'Amico M et al. A HERG current sustains a cardiac-type action potential in neuroblastoma S cells.
Biochem. Biophys. Res. Commun., 2003 Feb 28 , 302 (101-8).

2084

49950

2085

41865

2088

49431

Witchel HJ et al. Psychotropic drugs, cardiac arrhythmia, and sudden death.
, 2003 Feb , 23 (58-77).

2089

45407

Moreno I et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.
J. Pharmacol. Exp. Ther., 2003 Feb , 304 (862-73).

2090

46930

Bauer CK et al. HERG K(+) currents in human prolactin-secreting adenoma cells.
Pflugers Arch., 2003 Feb , 445 (589-600).

2091

38405

2092

134251

Witchel HJ et al. Antipsychotics, HERG and sudden death.
Br J Psychiatry, 2003 Feb , 182 (171-2).

2094

37831

2095

36696

Hurst RS et al. Dopamine receptor agonists differ in their actions on cardiac ion channels.
Eur. J. Pharmacol., 2003 Dec 15 , 482 (31-7).

2098

32243

2099

36421

Mizuno H et al. Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor.
Biol. Pharm. Bull., 2003 Dec , 26 (1661-7).

2100

30422

2102

39259

2103

48152

Keseru GM Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Bioorg. Med. Chem. Lett., 2003 Aug 18 , 13 (2773-5).

2105

46284

Ninomiya T et al. Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2).
J. Cardiovasc. Pharmacol., 2003 Aug , 42 (161-8).

2107

47989

2111

35259

Osanai S et al. Effect of HERG-like potassium channel blocker on the carotid body chemoreception.
Adv. Exp. Med. Biol., 2003 , 536 (117-22).

2112

37508

Bett GC et al. Functionally-distinct proton-binding in HERG suggests the presence of two binding sites.
Cell Biochem. Biophys., 2003 , 39 (183-93).

2114

44508

Karle CA et al. The antiarrhythmic drug BRL-32872.
, 2002 Summer , 20 (111-20).

2116

46433

Wang H et al. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation.
Cancer Res., 2002 Sep 1 , 62 (4843-8).

2117

46582

Zitron E et al. Bertosamil blocks HERG potassium channels in their open and inactivated states.
Br. J. Pharmacol., 2002 Sep , 137 (221-8).

2119

49254

Ohya S et al. Functional and molecular identification of ERG channels in murine portal vein myocytes.
Am. J. Physiol., Cell Physiol., 2002 Sep , 283 (C866-77).

2121

42105

2122

40847

Malykhina AP et al. Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes.
Eur. J. Pharmacol., 2002 Oct 11 , 452 (269-77).

2123

44632

2124

43349

Mullins FM et al. Extracellular sodium interacts with the HERG channel at an outer pore site.
J. Gen. Physiol., 2002 Oct , 120 (517-37).

2125

49749

Angelo K et al. KCNE5 induces time- and voltage-dependent modulation of the KCNQ1 current.
Biophys. J., 2002 Oct , 83 (1997-2006).

2126

49289

2127

43186

2128

47943

2129

48942

Jongbloed R et al. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome.
Hum. Mutat., 2002 Nov , 20 (382-91).

2130

40033

Bertaso F et al. Expression of voltage-gated K+ channels in human atrium.
Basic Res. Cardiol., 2002 Nov , 97 (424-33).

2131

44989

Katchman AN et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.
J. Pharmacol. Exp. Ther., 2002 Nov , 303 (688-94).

2132

48698

Cherubini A et al. HERG K+ channels and beta1 integrins interact through the assembly of a macromolecular complex.
Ann. N. Y. Acad. Sci., 2002 Nov , 973 (559-61).

2134

134476

Gima K et al. Ionic current basis of electrocardiographic waveforms: a model study.
Circ. Res., 2002 May 3 , 90 (889-96).

2135

48523

Tristani-Firouzi M et al. Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of HERG K+ channels.
J. Biol. Chem., 2002 May 24 , 277 (18994-9000).

2136

41407

Smith GA et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells.
J. Biol. Chem., 2002 May 24 , 277 (18528-34).

2139

41272

2142

49493

2145

41353

2146

44437

Jespersen T et al. Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.
BioTechniques, 2002 Mar , 32 (536-8, 540).

2147

47561

Smith PL et al. Fast and slow voltage sensor movements in HERG potassium channels.
J. Gen. Physiol., 2002 Mar , 119 (275-93).

2149

46276

Sánchez-Chapula JA et al. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
J. Biol. Chem., 2002 Jun 28 , 277 (23587-95).

2151

48705

2153

45007

2155

49164

Grunnet M et al. KCNE4 is an inhibitory subunit to the KCNQ1 channel.
J. Physiol. (Lond.), 2002 Jul 1 , 542 (119-30).

2157

40353

2160

40492

Finley MR et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart.
Am. J. Physiol. Heart Circ. Physiol., 2002 Jul , 283 (H126-38).

2161

48105

Gong Q et al. Role of glycosylation in cell surface expression and stability of HERG potassium channels.
Am. J. Physiol. Heart Circ. Physiol., 2002 Jul , 283 (H77-84).

2163

52859

Pardo-López L et al. Mapping the receptor site for ergtoxin, a specific blocker of ERG channels.
FEBS Lett., 2002 Jan 2 , 510 (45-9).

2164

46460

Bachmann A et al. Inhibition of cardiac potassium currents by pentobarbital.
Naunyn Schmiedebergs Arch. Pharmacol., 2002 Jan , 365 (29-37).

2165

43196

Benhorin J et al. Variable expression of long QT syndrome among gene carriers from families with five different HERG mutations.
Ann Noninvasive Electrocardiol, 2002 Jan , 7 (40-6).

2166

134583

Karle CA et al. An ion channel 'addicted' to ether, alcohol and cocaine: the HERG potassium channel.
Cardiovasc. Res., 2002 Jan , 53 (6-8).

2167

134581

2168

44403

Verheijck EE et al. Atrio-sinus interaction demonstrated by blockade of the rapid delayed rectifier current.
Circulation, 2002 Feb 19 , 105 (880-5).

2170

43259

Conrath CE et al. Gender differences in the long QT syndrome: effects of beta-adrenoceptor blockade.
Cardiovasc. Res., 2002 Feb 15 , 53 (770-6).

2173

45395

2174

45627

Weerapura M et al. Dofetilide block involves interactions with open and inactivated states of HERG channels.
Pflugers Arch., 2002 Feb , 443 (520-31).

2175

42319

Ohya S et al. Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle.
Am. J. Physiol. Gastrointest. Liver Physiol., 2002 Feb , 282 (G277-87).

2179

47214

Kushida S et al. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
Eur. J. Pharmacol., 2002 Dec 13 , 457 (19-27).

2180

47108

2181

42026

2182

49743

Wimmers S et al. Biophysical properties of heteromultimeric erg K+ channels.
Pflugers Arch., 2002 Dec , 445 (423-30).

2183

49304

Pietilä E et al. Association between HERG K897T polymorphism and QT interval in middle-aged Finnish women.
J. Am. Coll. Cardiol., 2002 Aug 7 , 40 (511-4).

2185

49561

Kongsamut S et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Eur. J. Pharmacol., 2002 Aug 16 , 450 (37-41).

2186

43866

Becchetti A et al. The functional properties of the human ether-à-go-go-like (HELK2) K+ channel.
Eur. J. Neurosci., 2002 Aug , 16 (415-28).

2188

43730

Xu X et al. Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy.
Am. J. Physiol. Heart Circ. Physiol., 2002 Aug , 283 (H664-70).

2189

49457

2190

48345

Cayabyab FS et al. Regulation of an ERG K+ current by Src tyrosine kinase.
J. Biol. Chem., 2002 Apr 19 , 277 (13673-81).

2191

40559

Kagan A et al. 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity.
EMBO J., 2002 Apr 15 , 21 (1889-98).

2193

42852

Leurs R et al. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects.
Clin. Exp. Allergy, 2002 Apr , 32 (489-98).

2197

44903

Sauviat MP et al. [Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane]
J. Soc. Biol., 2002 , 196 (339-48).

2198

51366

Fontana L et al. Long-term modulation of HERG channel gating in hypoxia.
Biochem. Biophys. Res. Commun., 2001 Sep 7 , 286 (857-62).

2199

53642

Chen J et al. The S4-S5 linker couples voltage sensing and activation of pacemaker channels.
Proc. Natl. Acad. Sci. U.S.A., 2001 Sep 25 , 98 (11277-82).

2200

50330

Finlayson K et al. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
Eur. J. Pharmacol., 2001 Oct 26 , 430 (147-8).

2201

59437

2202

53153

Pond AL et al. ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart.
Trends Cardiovasc. Med., 2001 Oct , 11 (286-94).

2203

56735

Ferreira S et al. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel.
J. Pharmacol. Exp. Ther., 2001 Oct , 299 (220-6).

2204

53265

2206

50888

Perkiömäki JS et al. Heart rate variability in patients with congenital long QT syndrome.
Ann Noninvasive Electrocardiol, 2001 Oct , 6 (298-304).

2207

58785

2210

56374

2211

43916

Ko YL et al. Linkage and mutation analysis in two Taiwanese families with long QT syndrome.
J. Formos. Med. Assoc., 2001 Nov , 100 (767-71).

2213

51858

Yang T et al. Drug block of I(kr): model systems and relevance to human arrhythmias.
J. Cardiovasc. Pharmacol., 2001 Nov , 38 (737-44).

2214

58872

Bachmann A et al. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Naunyn Schmiedebergs Arch. Pharmacol., 2001 Nov , 364 (472-8).

2215

57375

2217

53689

Tseng GN I(Kr): the hERG channel.
J. Mol. Cell. Cardiol., 2001 May , 33 (835-49).

2218

58014

Vandenberg JI et al. HERG K+ channels: friend and foe.
Trends Pharmacol. Sci., 2001 May , 22 (240-6).

2219

56278

2220

56084

2221

52610

Zhang S et al. Cocaine blocks HERG, but not KvLQT1+minK, potassium channels.
Mol. Pharmacol., 2001 May , 59 (1069-76).

2223

56406

2225

54466

Korolkova YV et al. An ERG channel inhibitor from the scorpion Buthus eupeus.
J. Biol. Chem., 2001 Mar 30 , 276 (9868-76).

2227

56337

Johnson JP et al. A novel extracellular calcium sensing mechanism in voltage-gated potassium ion channels.
J. Neurosci., 2001 Jun 15 , 21 (4143-53).

2228

55836

Wainger BJ et al. Molecular mechanism of cAMP modulation of HCN pacemaker channels.
Nature, 2001 Jun 14 , 411 (805-10).

2230

134758

De Backer MD et al. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.
Antimicrob. Agents Chemother., 2001 Jun , 45 (1660-70).

2232

58921

2233

59247

2234

53620

2235

52152

Shuba YM et al. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents.
Biochem. Pharmacol., 2001 Jul 1 , 62 (41-9).

2238

57640

Bajanowski T et al. Prolonged QT interval and sudden infant death--report of two cases.
Forensic Sci. Int., 2001 Jan 1 , 115 (147-53).

2240

50450

Wimmers S et al. Erg1, erg2 and erg3 K channel subunits are able to form heteromultimers.
Pflugers Arch., 2001 Jan , 441 (450-5).

2241

59006

Paul AA et al. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Biochem. Biophys. Res. Commun., 2001 Feb 9 , 280 (1243-50).

2243

54811

Lupoglazoff JM et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations.
Circulation, 2001 Feb 27 , 103 (1095-101).

2244

56591

Finlayson K et al. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Eur. J. Pharmacol., 2001 Feb 2 , 412 (203-12).

2246

57648

2247

51549

Karle CA et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
Cardiovasc. Res., 2001 Feb 1 , 49 (361-70).

2248

52204

O'Leary ME Inhibition of human ether-a-go-go potassium channels by cocaine.
Mol. Pharmacol., 2001 Feb , 59 (269-77).

2249

55462

González T et al. Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels.
J. Pharmacol. Exp. Ther., 2001 Feb , 296 (573-83).

2250

54954

Li BX et al. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes.
Acta Pharmacol. Sin., 2001 Feb , 22 (125-31).

2251

59380

2252

53365

Lu Y et al. Effects of premature stimulation on HERG K(+) channels.
J. Physiol. (Lond.), 2001 Dec 15 , 537 (843-51).

2253

52293

2256

56185

2257

50840

Kang J et al. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel.
Biochem. Biophys. Res. Commun., 2001 Aug 24 , 286 (499-504).

2259

58909

Kamiya K et al. Open channel block of HERG K(+) channels by vesnarinone.
Mol. Pharmacol., 2001 Aug , 60 (244-53).

2260

54692

Moschèn et al. Effects of gallium and mercury ions on transport systems.
J. Dent. Res., 2001 Aug , 80 (1753-7).

2261

53456

2264

51453

Bérubé J et al. Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian cell line.
J. Pharmacol. Exp. Ther., 2001 Apr , 297 (96-102).

2265

50180

Towbin JA et al. Genotype and severity of long QT syndrome.
Drug Metab. Dispos., 2001 Apr , 29 (574-9).

2267

55025

Mergenthaler J et al. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.
Naunyn Schmiedebergs Arch. Pharmacol., 2001 Apr , 363 (472-80).

2268

134773

2274

57780

Li H et al. Current concepts in long QT syndrome.
Pediatr Cardiol, 2000 Nov-Dec , 21 (542-50).

2275

59021

Drici MD et al. Cardiac K+ channels and drug-acquired long QT syndrome.
Therapie, 2000 Jan-Feb , 55 (185-93).

2276

58533

Georgijević Milić L [Molecular genetics in the hereditary form of long QT syndrome]
Med. Pregl., 2000 Jan-Feb , 53 (51-4).

2277

54397

Chouabe C et al. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs.
Therapie, 2000 Jan-Feb , 55 (195-202).

2279

54388

Tinel N et al. M-type KCNQ2-KCNQ3 potassium channels are modulated by the KCNE2 subunit.
FEBS Lett., 2000 Sep 1 , 480 (137-41).

2280

57671

2281

58291

Buckley NA et al. Cardiovascular adverse effects of antipsychotic drugs.
, 2000 Sep , 23 (215-28).

2282

134933

Mitcheson JS et al. A structural basis for drug-induced long QT syndrome.
Proc. Natl. Acad. Sci. U.S.A., 2000 Oct 24 , 97 (12329-33).

2283

51509

Bischoff U et al. Effects of fluoroquinolones on HERG currents.
Eur. J. Pharmacol., 2000 Oct 20 , 406 (341-3).

2285

52433

Ficker E et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol., 2000 Oct , 279 (H1748-56).

2287

52483

Witchel HJ et al. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Clin. Exp. Pharmacol. Physiol., 2000 Oct , 27 (753-66).

2288

57614

Numaguchi H et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Circ. Res., 2000 Nov 24 , 87 (1012-8).

2289

53517

Taglialatela M et al. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.
Br. J. Pharmacol., 2000 Nov , 131 (1081-8).

2290

56238

2291

54448

2296

54686

Tamargo J Drug-induced torsade de pointes: from molecular biology to bedside.
Jpn. J. Pharmacol., 2000 May , 83 (1-19).

2298

135018

Kuryshev YA et al. KChAP as a chaperone for specific K(+) channels.
Am. J. Physiol., Cell Physiol., 2000 May , 278 (C931-41).

2299

63968

Kang J et al. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide.
Eur. J. Pharmacol., 2000 Mar 31 , 392 (137-40).

2301

135061

2302

61337

Caballero R et al. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents.
Circulation, 2000 Mar 14 , 101 (1199-205).

2303

65915

Mitcheson JS et al. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
J. Gen. Physiol., 2000 Mar , 115 (229-40).

2305

62615

2306

135040

2307

51783

Cui J et al. Cyclic AMP regulates the HERG K(+) channel by dual pathways.
Curr. Biol., 2000 Jun 1 , 10 (671-4).

2308

51336

Sanchez-Chapula JA et al. Altered gating of HERG potassium channels by cobalt and lanthanum.
Pflugers Arch., 2000 Jun , 440 (264-74).

2309

51447

2313

134946

Hancox JC et al. Psychotropic drugs, HERG, and the heart.
Lancet, 2000 Jul 29 , 356 (428).

2315

50282

Weerapura M et al. State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes.
J. Physiol. (Lond.), 2000 Jul 15 , 526 Pt 2 (265-78).

2316

54700

Chiang CE et al. The long QT syndromes: genetic basis and clinical implications.
J. Am. Coll. Cardiol., 2000 Jul , 36 (1-12).

2317

54180

Kiehn J Regulation of the cardiac repolarizing HERG potassium channel by protein kinase A.
Trends Cardiovasc. Med., 2000 Jul , 10 (205-9).

2318

52889

2321

54379

2322

65321

2323

66396

Schroeder BC et al. A constitutively open potassium channel formed by KCNQ1 and KCNE3.
Nature, 2000 Jan 13 , 403 (196-9).

2324

60191

Terai T et al. Effects of external acidosis on HERG current expressed in Xenopus oocytes.
J. Mol. Cell. Cardiol., 2000 Jan , 32 (11-21).

2326

68362

2328

61869

2329

51364

2332

50748

January CT et al. Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.
J. Cardiovasc. Electrophysiol., 2000 Dec , 11 (1413-8).

2333

57562

Gögelein H et al. Inhibition of IKs channels by HMR 1556.
Naunyn Schmiedebergs Arch. Pharmacol., 2000 Dec , 362 (480-8).

2337

50643

Tie H et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine.
Br. J. Pharmacol., 2000 Aug , 130 (1967-75).

2338

59680

Kagan A et al. The dominant negative LQT2 mutation A561V reduces wild-type HERG expression.
J. Biol. Chem., 2000 Apr 14 , 275 (11241-8).

2339

67611

2341

68079

Jo SH et al. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline.
Br. J. Pharmacol., 2000 Apr , 129 (1474-80).

2343

55910

Leenhardt A et al. [Present concepts of congenital long QT syndrome]
Arch Mal Coeur Vaiss, 2000 Apr , 93 (17-21).

2344

50077

2346

135160

Hoorntje T et al. Homozygous premature truncation of the HERG protein : the human HERG knockout.
Circulation, 1999 Sep 21 , 100 (1264-7).

2350

60151

2351

68870

Wang HZ et al. Inactivation gating determines nicotine blockade of human HERG channels.
Am. J. Physiol., 1999 Sep , 277 (H1081-8).

2352

63919

Yoshida H et al. Characterization of a novel missense mutation in the pore of HERG in a patient with long QT syndrome.
J. Cardiovasc. Electrophysiol., 1999 Sep , 10 (1262-70).

2353

63228

Lee-Chen GJ et al. Romano-Ward long QT syndrome: identification of a HERG mutation in a Taiwanese kindred.
J. Formos. Med. Assoc., 1999 Sep , 98 (649-52).

2354

60260

2356

62965

Jiang M et al. Mechanism for the effects of extracellular acidification on HERG-channel function.
Am. J. Physiol., 1999 Oct , 277 (H1283-92).

2357

69382

Robbins J et al. Genetic variation affecting heart rate in Drosophila melanogaster.
Genet. Res., 1999 Oct , 74 (121-8).

2358

68471

Sepp R et al. [Molecular genetics of the long QT syndrome: clinical aspects]
, 1999 Nov 21 , 140 (2633-8).

2359

135078

2360

135077

Nakajima T et al. Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2.
Cardiovasc. Res., 1999 Nov , 44 (283-93).

2361

241586

Johnson JP et al. Enhancement of HERG K+ currents by Cd2+ destabilization of the inactivated state.
Biophys. J., 1999 Nov , 77 (2534-41).

2363

69739

2364

68419

Viswanathan PC et al. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study.
Cardiovasc. Res., 1999 May , 42 (530-42).

2367

64759

Chen Q et al. Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome.
Circulation, 1999 Mar 16 , 99 (1344-7).

2368

69620

Sansom MS Ion channels: structure of a molecular brake.
Curr. Biol., 1999 Mar 11 , 9 (R173-5).

2370

64190

2371

61933

Kiehn J et al. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
Naunyn Schmiedebergs Arch. Pharmacol., 1999 Mar , 359 (212-9).

2372

61369

Chachin M et al. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel.
Eur. J. Pharmacol., 1999 Jun 25 , 374 (457-60).

2373

65998

Jo SH et al. Blockade of HERG channels expressed in Xenopus oocytes by external H+.
Pflugers Arch., 1999 Jun , 438 (23-9).

2374

69269

2376

61379

Schäfer R et al. The erg-like potassium current in rat lactotrophs.
J. Physiol. (Lond.), 1999 Jul 15 , 518 ( Pt 2) (401-16).

2377

66339

Yap YG et al. Arrhythmogenic mechanisms of non-sedating antihistamines.
Clin. Exp. Allergy, 1999 Jul , 29 Suppl 3 (174-81).

2378

64294

Kiehn J et al. Pathways of HERG inactivation.
Am. J. Physiol., 1999 Jul , 277 (H199-210).

2379

69182

Anumonwo JM et al. Proton and zinc effects on HERG currents.
Biophys. J., 1999 Jul , 77 (282-98).

2380

60094

Taglialatela M et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity.
Clin. Exp. Allergy, 1999 Jul , 29 Suppl 3 (182-9).

2381

65681

Meves H et al. Separation of M-like current and ERG current in NG108-15 cells.
Br. J. Pharmacol., 1999 Jul , 127 (1213-23).

2382

60050

2384

135272

El-Sherif N et al. The long QT syndrome and torsade de pointes.
Pacing Clin Electrophysiol, 1999 Jan , 22 (91-110).

2385

64800

Petrecca K et al. N-linked glycosylation sites determine HERG channel surface membrane expression.
J. Physiol. (Lond.), 1999 Feb 15 , 515 ( Pt 1) (41-8).

2386

65098

Sanguinetti MC et al. Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes.
J. Physiol. (Lond.), 1999 Feb 1 , 514 ( Pt 3) (667-75).

2387

67746

Tan HL et al. Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2).
J. Cardiovasc. Electrophysiol., 1999 Feb , 10 (229-33).

2388

60551

Po SS et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
J. Cardiovasc. Pharmacol., 1999 Feb , 33 (181-5).

2391

68154

Davis MW et al. A mutation in the C. elegans EXP-2 potassium channel that alters feeding behavior.
Science, 1999 Dec 24 , 286 (2501-4).

2392

60808

2394

62666

Akbarali HI et al. Role of HERG-like K(+) currents in opossum esophageal circular smooth muscle.
Am. J. Physiol., 1999 Dec , 277 (C1284-90).

2395

68209

Jiang M et al. Use-dependent 'agonist' effect of azimilide on the HERG channel.
J. Pharmacol. Exp. Ther., 1999 Dec , 291 (1324-36).

2396

66298

2398

69611

Wang H et al. Inactivation block of the HERG human cardiac K+ channels by RP58866.
Br. J. Pharmacol., 1999 Aug , 127 (1899-907).

2399

61667

Bérubé J et al. Modulation of HERG potassium channel properties by external pH.
Pflugers Arch., 1999 Aug , 438 (419-22).

2400

68317

2403

68019

Ganetzky B et al. The eag family of K+ channels in Drosophila and mammals.
Ann. N. Y. Acad. Sci., 1999 Apr 30 , 868 (356-69).

2404

60366

Sanguinetti MC Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.
Ann. N. Y. Acad. Sci., 1999 Apr 30 , 868 (406-13).

2405

66917

Matsuoka R et al. A mitochondrial DNA mutation cosegregates with the pathophysiological U wave.
Biochem. Biophys. Res. Commun., 1999 Apr 2 , 257 (228-33).

2406

63238

2407

61844

Trudeau MC et al. Functional analysis of a mouse brain Elk-type K+ channel.
J. Neurosci., 1999 Apr 15 , 19 (2906-18).

2408

69987

2411

67706

2413

67286

Jongbloed RJ et al. Novel KCNQ1 and HERG missense mutations in Dutch long-QT families.
Hum. Mutat., 1999 , 13 (301-10).

2414

62858

2416

64527

2418

60784

Barros F et al. Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.
J. Physiol. (Lond.), 1998 Sep 1 , 511 ( Pt 2) (333-46).

2419

68497

2423

62036

Janse MJ et al. Molecular mechanisms of arrhythmias.
, 1998 Oct , 17 Suppl 2 (II41-6).

2424

61710

Rosati B et al. Sulfonylureas blockade of neural and cardiac HERG channels.
FEBS Lett., 1998 Nov 27 , 440 (125-30).

2431

71722

Arcangeli A et al. Long-term exposure to retinoic acid induces the expression of IRK1 channels in HERG channel-endowed neuroblastoma cells.
Biochem. Biophys. Res. Commun., 1998 Mar 27 , 244 (706-11).

2432

72779

Ho WK et al. Voltage-dependent blockade of HERG channels expressed in Xenopus oocytes by external Ca2+ and Mg2+.
J. Physiol. (Lond.), 1998 Mar 15 , 507 ( Pt 3) (631-8).

2433

79984

Ackerman MJ The long QT syndrome: ion channel diseases of the heart.
Mayo Clin. Proc., 1998 Mar , 73 (250-69).

2434

73295

2435

78432

Mitrovic N et al. Independent versus coupled inactivation in sodium channels. Role of the domain 2 S4 segment.
J. Gen. Physiol., 1998 Mar , 111 (451-62).

2436

76577

Nagai R et al. [Molecular genetics of cardiovascular diseases]
Rinsho Byori, 1998 Mar , 46 (249-57).

2437

64637

2438

64431

Fung D et al. RsaI and MaeI intragenic RFLPs in the human HERG gene.
Clin. Genet., 1998 Jun , 53 (504).

2439

76155

Pennefather PS et al. Idiosyncratic gating of HERG-like K+ channels in microglia.
J. Gen. Physiol., 1998 Jun , 111 (795-805).

2440

70903

Zhou W et al. HERG-like K+ channels in microglia.
J. Gen. Physiol., 1998 Jun , 111 (781-94).

2441

79485

Kanters JK et al. Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome.
J. Cardiovasc. Electrophysiol., 1998 Jun , 9 (620-4).

2442

66706

Splawski I et al. Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1.
Genomics, 1998 Jul 1 , 51 (86-97).

2445

62091

Lewalter T et al. [QT syndrome: new diagnostic possibilities]
, 1998 Jul , 87 (517-21).

2447

72739

Busch AE et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
Br. J. Pharmacol., 1998 Jan , 123 (23-30).

2449

71581

Ficker E et al. Molecular determinants of dofetilide block of HERG K+ channels.
Circ. Res., 1998 Feb 23 , 82 (386-95).

2451

74649

Wang Q et al. Genetics, molecular mechanisms and management of long QT syndrome.
Ann. Med., 1998 Feb , 30 (58-65).

2452

64721

Hancox JC et al. Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation.
Biochem. Biophys. Res. Commun., 1998 Dec 30 , 253 (719-24).

2453

64896

Engeland B et al. Cloning and functional expression of rat ether-à-go-go-like K+ channel genes.
J. Physiol. (Lond.), 1998 Dec 15 , 513 ( Pt 3) (647-54).

2454

64995

Wattanasirichaigoon D et al. Molecular genetics of long-QT syndrome.
Curr. Opin. Pediatr., 1998 Dec , 10 (628-34).

2455

64015

2456

77416

2457

63213

2458

68059

2459

68136

Eder C Ion channels in microglia (brain macrophages).
Am. J. Physiol., 1998 Aug , 275 (C327-42).

2460

67317

Dumaine R et al. Blockade of HERG and Kv1.5 by ketoconazole.
J. Pharmacol. Exp. Ther., 1998 Aug , 286 (727-35).

2462

135392

Li H et al. New mutations in the KVLQT1 potassium channel that cause long-QT syndrome.
Circulation, 1998 Apr 7 , 97 (1264-9).

2463

75684

Meyer R et al. Characterization of an eag-like potassium channel in human neuroblastoma cells.
J. Physiol. (Lond.), 1998 Apr 1 , 508 ( Pt 1) (49-56).

2465

71648

2466

77244

2467

71934

Akimoto K et al. Novel missense mutation (G601S) of HERG in a Japanese long QT syndrome family.
Hum. Mutat., 1998 , Suppl 1 (S184-6).

2470

70318

Suessbrich H et al. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
FEBS Lett., 1997 Sep 8 , 414 (435-8).

2471

78501

2472

79360

van den Berg MH et al. The long QT syndrome: a novel missense mutation in the S6 region of the KVLQT1 gene.
Hum. Genet., 1997 Sep , 100 (356-61).

2473

77154

Taglialatela M et al. Regulation of the human ether-a-gogo related gene (HERG) K+ channels by reactive oxygen species.
Proc. Natl. Acad. Sci. U.S.A., 1997 Oct 14 , 94 (11698-703).

2474

74688

2475

77254

Wang S et al. Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation.
FEBS Lett., 1997 Nov 3 , 417 (43-7).

2477

70908

2480

77373

Wang Q et al. Molecular genetics of long QT syndrome from genes to patients.
Curr. Opin. Cardiol., 1997 May , 12 (310-20).

2481

76059

Zou A et al. Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes.
Am. J. Physiol., 1997 Mar , 272 (H1309-14).

2483

76969

Chiesa N et al. A novel role for HERG K+ channels: spike-frequency adaptation.
J. Physiol. (Lond.), 1997 Jun 1 , 501 ( Pt 2) (313-8).

2484

71734

Le Marec H et al. [Congenital long QT syndromes]
Arch Mal Coeur Vaiss, 1997 Jun , 90 Spec No 3 (25-35).

2485

77674

McDonald TV et al. A minK-HERG complex regulates the cardiac potassium current I(Kr).
Nature, 1997 Jul 17 , 388 (289-92).

2486

76846

Wang S et al. A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes.
J. Physiol. (Lond.), 1997 Jul 1 , 502 ( Pt 1) (45-60).

2487

74191

Ducic I et al. Comparative effects of loratadine and terfenadine on cardiac K+ channels.
J. Cardiovasc. Pharmacol., 1997 Jul , 30 (42-54).

2489

77300

Tanaka T et al. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome.
Circulation, 1997 Feb 4 , 95 (565-7).

2490

70046

Titus SA et al. The Drosophila erg K+ channel polypeptide is encoded by the seizure locus.
J. Neurosci., 1997 Feb 1 , 17 (875-81).

2491

73525

Wang XJ et al. The seizure locus encodes the Drosophila homolog of the HERG potassium channel.
J. Neurosci., 1997 Feb 1 , 17 (882-90).

2492

71745

Wymore RS et al. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.
Circ. Res., 1997 Feb , 80 (261-8).

2493

75481

2496

71154

2497

74507

Priori SG et al. Molecular biology of the long QT syndrome: impact on management.
, 1997 Aug , 20 (2052-7).

2498

79794

Kimura T et al. [A family with facioscapulohumeral muscular dystrophy and hereditary long QT syndrome]
Rinsho Shinkeigaku, 1997 Aug , 37 (690-2).

2500

79388

Ko CM et al. Suppression of mammalian K+ channel family by ebastine.
J. Pharmacol. Exp. Ther., 1997 Apr , 281 (233-44).

2501

74484

Sanguinetti MC et al. Molecular physiology of cardiac delayed rectifier K+ channels.
, 1997 , Suppl 12 (170-2).

2502

78136

2503

76842

Priori SG et al. A molecular basis for the therapy of the long QT syndrome.
Arch Mal Coeur Vaiss, 1996 Sep , 89 (1185-7).

2504

74296

Satler CA et al. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome.
Am. J. Med. Genet., 1996 Oct 2 , 65 (27-35).

2507

79585

Faravelli L et al. A HERG-like K+ channel in rat F-11 DRG cell line: pharmacological identification and biophysical characterization.
J. Physiol. (Lond.), 1996 Oct 1 , 496 ( Pt 1) (13-23).

2508

70581

2509

135560

2510

74028

Guatteo E et al. A novel K+ channel blocker isolated from 'hiccup nut' toxin.
Neuroreport, 1996 Nov 4 , 7 (2575-9).

2511

74974

2513

135624

Trudeau MC et al. HERG sequence correction.
Science, 1996 May 24 , 272 (1087).

2514

83195

Benson DW et al. Missense mutation in the pore region of HERG causes familial long QT syndrome.
Circulation, 1996 May 15 , 93 (1791-5).

2515

88171

Spector PS et al. Fast inactivation causes rectification of the IKr channel.
J. Gen. Physiol., 1996 May , 107 (611-9).

2516

88128

Sanguinetti MC et al. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia.
Proc. Natl. Acad. Sci. U.S.A., 1996 Mar 5 , 93 (2208-12).

2517

83440

Nakajima T et al. [Long QT syndrome]
Nippon Rinsho, 1996 Mar , 54 (776-81).

2519

75891

Schönherr R et al. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel.
J. Physiol. (Lond.), 1996 Jun 15 , 493 ( Pt 3) (635-42).

2520

82690

Snyders DJ et al. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Mol. Pharmacol., 1996 Jun , 49 (949-55).

2522

87576

Russell MW et al. The molecular genetics of the congenital long QT syndromes.
Curr. Opin. Cardiol., 1996 Jan , 11 (45-51).

2523

135643

Smith PL et al. The inward rectification mechanism of the HERG cardiac potassium channel.
Nature, 1996 Feb 29 , 379 (833-6).

2524

88298

Lazzara R Mechanisms and management of congenital and acquired long QT syndromes.
Arch Mal Coeur Vaiss, 1996 Feb , 89 Spec No 1 (51-5).

2526

135594

2528

86517

Robertson GA et al. Potassium currents expressed from Drosophila and mouse eag cDNAs in Xenopus oocytes.
Neuropharmacology, 1996 , 35 (841-50).

2529

83345

Roden DM et al. Recent advances in understanding the molecular mechanisms of the long QT syndrome.
J. Cardiovasc. Electrophysiol., 1995 Nov , 6 (1023-31).

2530

88465

2531

86382

2532

135701

Trudeau MC et al. HERG, a human inward rectifier in the voltage-gated potassium channel family.
Science, 1995 Jul 7 , 269 (92-5).

2535

87550

2538

304700

Zarrindast MR et al. Involvement of GABAA receptor sites in diazepam hypothermia.
Gen. Pharmacol., 1989 , 20 (855-9).